REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

SCIENTIFIC INFORMATION ON HEALTHCARE DISRUPTION

PIER MARIA FORNASARI
2021-11-27

A systematic review on Blockchain applications in health care for COVID-19 and beyond published on The Lancet Digital Health

The COVID-19 pandemic has had a substantial and global impact on health care and has greatly accelerated the adoption of digital technology. One of these emerging digital technologies, blockchain, has unique characteristics (eg, immutability, decentralisation, and transparency) that can be useful in multiple domains (eg, management of electronic medical records and access rights, and mobile

No Comments InDIGITAL HEALTH

PIER MARIA FORNASARI
2021-11-27

Scientific analysis of COVID death data incorrectly manipulated to demonstrate vaccines are ineffective or worse: that’s not the reality

Social media posts commenting on data from the UK, Israel and South Africa, among others, claim deaths from COVID (or all deaths) are now higher in vaccinated than unvaccinated citizens. Others make the more moderate claim vaccines do nothing to prevent death from COVID. These reports appear intimidating, because they usually utilise real data or statistics. Many of the raw numbers presented are

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-27

Nearly half a million lives saved by COVID-19 vaccination only among people over 60 in less than a year in Europe following a WHO/ECDC study

A new study by the WHO Regional Office for Europe and European Centre for Disease Prevention and Control (ECDC) published in Eurosurveillance estimates that 470,000 lives have been saved among those aged 60 years and over since the start of COVID-19 vaccination roll-out in 33 countries across the WHO European Region. This estimate does not

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-25

A small cluster of SARS_CoV-2 B.1.1.529 new variant with 32 spike protein mutations identified in Botswana and in Gauteng Province in South Africa

A new variant of COVID-19 identified in Botswana and Nigeria with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. The B.1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear

2 comments InCovid-19

PIER MARIA FORNASARI
2021-11-20

Review on Covid-19 Vaccine-induced immune thrombotic thrombocytopenia published in The Lancet Haematology

In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested, and introduced at a remarkable speed. Although the vaccine introduction had a major impact on the evolution of COVID-19, some potential rare side-effects of the vaccines were observed. Within a short period, three scientific groups from Norway, Germany, and the UK reported cerebral

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-20

Harms Linked to Unapproved Stem Cell Interventions Highlight Need for Greater FDA Enforcement

Unproven regenerative medical products have led to infections, disabilities, and deaths Stem cell products and other regenerative therapies have significant potential to treat traumatic injuries and serious diseases. Although some have earned approval from the Food and Drug Administration, most have not, and many of these unapproved interventions have led to life-threatening infections, chronic pain,

No Comments InUNPROVEN THERAPIES

PIER MARIA FORNASARI
2021-11-20

UCalgary study shows how desamethasone, used to treat critically ill COVID-19 patients, modulates immature neutrophils and interferon programming and why drug may only benefit males

Research into the way our immune systems respond to COVID-19 reveals the sex of a patient may affect how well drugs work Anew study from the University of Calgary shows how dexamethasone, the main treatment for severe COVID-19 lung infections, alters how immune cells work, which may help male patients, but has little to no benefit for

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-19

New analysis predicts how well vaccines will work against COVID-19 strains

Vaccines are less effective against some COVID-19 variants and boosting may be required within one year to maintain efficacy above 50 per cent, according to a new study. The researchers from the Sydney Institute for Infectious Diseases at the University of Sydney, UNSW Sydney’s Kirby Institute and the University of Melbourne’s Doherty Institute have conducted an analysis

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-18

Early Convalescent Plasma for High-Risk Outpatients with Covid-19: results of a new trial published in NEJM confirm failure

The object of the study was to verify if early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) could prevent disease progression in acutely ill, high-risk patients with Covid-19. In this randomized, multicenter, single-blind trial, we assigned patients who were being treated in an emergency department for

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-18

Gene therapy effective in children with severe Hurler’s syndrome: the treatment, developed by SR-Tiget in Milan published in NEJM

The first tests on eight children show favorable preliminary results, with an adjustment of motor and cognitive skills and improvements in some brain and joint parameters Gene therapy takes steps forward in the fight against rare diseases. Eight children with severe Hurler’s syndrome, a disease associated with reduced life expectancy, benefited from this therapy. The

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-11-17

First Data show Pfizer PF-07321332 Protease Inhibitor pill is effective in Preventing Severe COVID-19

Over the course of this pandemic, significant progress has been made in treating COVID-19 and helping to save lives. That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs, to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has made a major contribution. But for many months we’ve had hopes that a

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-17

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell (CAR T) therapy has revolutionized the field of malignant hematology. CD19-targeted CAR T-cell therapy has resulted in effective, often durable, responses for chemotherapy-refractory B-cell lymphoma and B-acute lymphoblastic leukemia (B-ALL) in prospective clinical trials. CAR T cells against B-cell maturation antigen have also shown overall response rates in the range of

No Comments InCAR-T

PIER MARIA FORNASARI
2021-11-17

Monash University study uncovers a new understanding of how mesenchymal stromal cells benefit patients in cell therapy

The therapeutic benefit to patients receiving mesenchymal stromal cell (MSC) therapy is not because the injected cells remain viable, but because of cell death, researchers at the Monash Biomedicine Discovery Institute (BDI) have found. In recent years, significant efforts have been made to develop stem cell-based therapies for difficult-to-treat diseases. MSC therapy is regenerative cell-based

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2021-11-13

Low-molecular-weight heparin use in Covid-19 is associated with curtailed viral persistence: a retrospective multicentre observational study

Clotting problems and resulting complications are common in COVID-19 patients. Researchers at the Medical University of Vienna have now shown that a member of the anticoagulant group of drugs not only has a beneficial effect on survival of COVID-19 patients, but also influences the duration of active infection with the SARS-CoV-2 coronavirus. The results were

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-13

New research by Boston Children’s Hospital on ricolinostat repurposing to curb neutrophil extracellular traps (NETs) and to fight severe inflammation in Covid-19

As we’ve seen during the COVID-19 pandemic, serious infections sometimes trigger an excessive inflammatory reaction that does as much harm — or more — than the infection itself. New research at Boston Children’s Hospital and Brigham and Women’s Hospital suggests a potential way to block this hyperinflammation response by repurposing or modifying an existing drug.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-12

Direct Comparison of Antibody Responses to Pfizer, Astrazeneca, Sputnik V and Sinopharm SARS-CoV-2 Vaccines in Mongolia: study published in Cell Host & Microbe by Stanford University

Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. In thi paper the authors collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-12

Study reveals tactics used by US stem cell clinics to market their treatments

Stem cell clinics continue to thrive in the US and worldwide, building their business on misleading advertising and offering unapproved and unproven stem-cell-based interventions (SCBI). A research recently published in Stem Cell Reports by Emma Frow, David Brafman, and colleagues from Arizona State University, asked what kinds of claims and evidence these clinics use to market their

No Comments InUNPROVEN THERAPIES

PIER MARIA FORNASARI
2021-11-12

Covid-19 vaccines protection against hospitalization and ICU effectiveness dropping over time: results in different studies

As millions of eligible people consider getting a booster shot, many are wondering what the data tells us about the effectiveness of the vaccines, and how much their protection might be waning. The good news is that a growing body of research shows that the vaccines authorized remain highly protective against severe disease and hospitalization

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-10

SARS-CoV-2 uses sugars to invade human cells, new study by University of Alberta shows

Understanding the process could help scientists look out for new, more infectious variants. Sugars found on the surface of human cells influence COVID-19 infection, according to a University of Alberta-led study that is one of the first to observe this relationship and suggests that cells in the brain might be particularly susceptible. “The idea here is that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-10

Novel mesenchymal stem cell therapy approach proves effective in treating COVID-19

An international team of researchers has advanced a new therapeutic approach using stem cells to treat COVID-19. Despite many advances in treating the COVID-19 virus there remains no specific cure for patients with infection. This is especially the case with hospitalised patients who end up in the ICU requiring mechanical ventilation support. Key members of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-10

Cell therapies, Gene therapy and CAR-T cells highlighted in EFPIA Pipeline Review 2021 Update

The new EFPIA Pipeline Review reveals that infectious, inflammatory, cancer, Alzheimer’s and rare disesases areas are among the top priorities of researchers running clinical trials today to investigate new medicines and vaccines. The comprehensive report found that in 2020 alone, around 5,000 clinical trials were launched – despite the disruption caused by the COVID-19 pandemic. In fact, the volume of trials has

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2021-11-09

BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age evaluation paper published in NEJM

Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age. A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-09

An Israeli Study published in NEJM Shows COVID-19 Immunity Waning over Time

The winter holidays are approaching, and among the many things to be grateful for this year is that nearly 200 million Americans are fully vaccinated for COVID-19. That will make it safer to spend time with friends and family, though everyone should remain vigilant just to be on the safe side. Though relatively uncommon, breakthrough

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-09

Ernst & Young white paper details how the Cell Gene Therapy industry can collaborate to advance the field

Harnessing the power of cell and gene therapies will require a next-generation level of collaboration not seen before the COVID-19 pandemic. In brief Before cell and gene therapies can meet increasing demand at the necessary speed and scale, the industry must address key challenges. A fractured supply chain, complicated manufacturing and unprecedented pricing are among

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-11-09

Pfizer’s novel COVID-19 oral antiviral protease inhibitor reduced risk of hospitalization or death by 89% in interm analysis of Phase 2/3 EPIC-HR study

PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo Pfizer plans to submit the data as

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-07

The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study published in Blood

In the last issue of Blood, Boulos et al analyze the cost-effectiveness of factor IX gene therapy in patients with severe hemophilia B, in a microsimulation Markov model. Hemophilia is an X-linked disease that affects 400000 people worldwide, of whom 15% have hemophilia B caused by deficiency of factor IX (FIX), which affected the offspring of Queen Victoria,

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-11-06

Oxford University researchers uncover gene that doubles risk of death from COVID-19

Scientists at Oxford University have identified the gene responsible for doubling the risk of respiratory failure from COVID-19. Sixty percent of people with South Asian ancestry carry the high-risk genetic signal, partly explaining the excess deaths seen in some UK communities, and the impact of COVID-19 in the Indian subcontinent. Previous work has already identified

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-05

SP-101, an investigational inhaled gene therapy for cystic fibrosis, shows potential in animal study

Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic fibrosis (CF) who are unable to benefit from current treatments, effectively increased CFTR gene activity in a ferret model of the disease, the company reported. Katherine Excoffon, PhD, Spirovant’s vice president of research, presented the data at the 2021 North American Cystic Fibrosis Conference (NACFC). Her

No Comments InCYSTIC FIBROSIS GENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-11-05

Breakthrough Infection Study Compares Decline in Covid-19 Vaccine Effectiveness and Consequences for Mortality

A new study in the leading journal Science reviewed COVID-19 breakthrough infections among 780,225 Veterans, finding that vaccine protection declined from 87.9% to 48.1% during the 2021 Delta surge in the U.S. The researchers from PHI, the Veterans Affairs Medical Center and the University of Texas Health Science Center found a dramatic decline in effectiveness

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-04

The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. Ethical issues and misinformation linked to overhyped science.

In March 2021, 1,480 U.S. businesses operating 2,754 clinics were found selling purported stem cell treatments for various indications. More than four times as many businesses than were identified 5 years ago are selling stem cell products that are not FDA-approved and lack convincing evidence of safety and efficacy following a new paper published in Cell

No Comments InUNPROVEN THERAPIES

PIER MARIA FORNASARI
2021-11-04

Tel Aviv University researchers have succeeded in identifying the SARS-CoV2 proteins that can damage endothelial cells

Nearly two years since becoming a global pandemic that has killed millions of people, the mystery of which proteins in the SARS-CoV-2 virus are responsible for severe vascular damage that could even lead to heart attack or stroke has not yet been solved. Now, for the first time, a team of experts led by Tel

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-04

Children Hospital of Philadelphia Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches,

No Comments InCAR-T

PIER MARIA FORNASARI
2021-11-03

A review on Mesenchymal stem cells-derived exosomes for drug delivery

Mesenchymal stem cells (MSCs) are multi-functional stem cells that are present in multiple human tissues and can be found in the spinal cord, umbilical cord blood, umbilical cord tissue, placenta tissue, adipose tissue, etc.. With low immunogenicity, multi-directional diferentiation ability, in particular homing ability, MSCs have signifcant research potential in cardiovascular diseases, nervous diseases, and

No Comments InEXOSOMES

PIER MARIA FORNASARI
2021-11-03

Stem cell treatment failed to reduce inflammation in Multiple Sclerosis

Treatment with mesenchymal stem cells (MSCs) has failed to significantly reduce inflammation in the brain of adults with multiple sclerosis (MS) in a phase 2 clinical trial. The into-the-vein treatment also failed to improve other clinical aspects of the condition. The results were shared in a study titled “Safety, tolerability, and activity of mesenchymal stem cells versus placebo

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-11-01

Serine protease inhibitor Nafamostat may be beneficial in the treatment of high-risk COVID-19 patients requiring oxygen treatment: results of a randomised Phase II clinical trial published in EClinical Medicine.

Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-19 pneumonia. This phase 2 open-label, randomised, multicentre, controlled trial evaluated nafamostat (4.8 mg/kg/day) plus standard-of-care (SOC) in hospitalised patients with COVID-19 pneumonia (i.e.,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-11-01

Long-term persistence of SARS-CoV-2 neutralizing antibody responses after Covid-19 infection: levels conferring 50% protection are maintained for around 990 days post-symptom onset.

In a paper published on The lancet researchers of University of Hong Kong used 50% plaque reduction neutralization test (PRNT) antibody titre data from 115 sera collected longitudinally from 90 to 386 days after onset of symptoms or first RT-PCR confirmation from 62 RT–PCR confirmed SARS-CoV infected individuals, to estimate that PRNT antibody will remain

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-28

Lifelong calcium and 25-hydroxyvitamin D use may shorten life expectancy and increase the risk of cardiovascular disease: a Karolinska Institute study shows.

Supplementation with calcium and vitamin D, alone or together, leads to increases in serum calcium (S-Ca) concentration with a peak 4 h after each ingestion and a more long-lasting elevation in serum 25-hydroxyvitamin D (S-25(OH)D), the marker metabolite for vitamin D status. Whether regular calcium supplementation elevates S-Ca after several months of use is debatable

No Comments InWELLNESS

PIER MARIA FORNASARI
2021-10-27

Gene Therapies against Rare diseases Boosted by NIH, FDA and Industry Alliance

The National Institutes of Health, U.S. Food and Drug Administration, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease. While there are approximately 7,000 rare diseases, only two heritable diseases currently have FDA-approved gene therapies. The newly launched Bespoke

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-10-23

Gene Therapy Up to Date

After numerous setbacks at the turn of the century, gene therapy is treating diseases ranging from neuromuscular disorders to cancer to blindness. The success is often qualified, however. Some of these therapies have proved effective at alleviating disease but come with a high price tag and other accessibility issues: Even when people know that a

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-10-23

Gene Therapy Shows Early Promise as Angelman Syndrome Treatment

The new therapy was generally well-tolerated and prevented key signs of the condition in animal models. Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities. Angelman

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-10-22

Alberta University researchers team uncovers new proteases inhibitors to slow SARS-CoV-2 replication mechanism

Novel protease inhibitors show promise for developing safer, more effective COVID-19 treatments. A team of researchers at the University of Alberta has uncovered new antiviral agents that could lead to safer and more effective COVID-19 treatments than other current drugs under development. In a recently published paper in the Journal of Medicinal Chemistry, the researchers identified novel protease

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-22

Patients with severe COVID-19 could benefit from higher doses of corticosteroids

A large international study in hospitalised patients with severe COVID-19 has shown that while a higher dose of steroids did not significantly reduce mortality, there was a trend towards benefit without increased side effects. Published today in the Journal of the American Medical Association, the study compared the standard 6mg dose of the steroid dexamethasone

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-21

Previously SARS-CoV-2 infected, if unvaccinated: reinfection by SARS-CoV-2 is likely, study finds

Throughout the COVID-19 pandemic, there has been much uncertainty about how long immunity lasts after an unvaccinated person is infected with SARS-CoV-2. Now a team of scientists led by faculty at Yale School of Public Health and the University of North Carolina at Charlotte have an answer: Strong protection following natural infection is short-lived. “Reinfection

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-19

COVID-19 Vaccines guarantee protection to non immune family members too

Risk of COVID-19 in families with two to five members. An interesting new study published in the journal JAMA Internal Medicine examines the risk of coronavirus disease 2019 (COVID-19) to a susceptible individual who is part of a family with COVID-19 immunity. Study: Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-19

Covid-19: no outcome improval by Interferon

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-18

Who’s at higher risk of serious symptoms for Covid-19?

Health conditions, such as heart or lung disease, can increase your risk of developing dangerous symptoms if you become infected with coronavirus disease 2019 (COVID-19). Coronavirus disease 2019 (COVID-19) symptoms can vary widely. Some people have no symptoms at all, while others become so sick that they eventually need mechanical assistance to breathe. The risk

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-18

How many people get ‘long COVID?’ More than half, researchers find.

Half of COVID survivors experience lingering symptoms six months after recovery More than half of the 236 million people who have been diagnosed with COVID-19 worldwide since December 2019 will experience post-COVID symptoms — more commonly known as “long COVID” — up to six months after recovering, according to Penn State College of Medicine researchers. The research

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-18

Cell-based therapies for retinal diseases: review of clinical trials and direct to consumer “cell therapy” clinics

This review aims to outline the particular approaches in the different published clinical trials for cell-based therapies for retinal diseases. The retinal pigment epithelium (RPE) is implicated in the pathophysiology of many retinal degenerative diseases. This cell layer is also an ideal target for cell-based therapies. Several early phase clinical trials evaluatingcell therapy approaches for

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2021-10-10

CRISPR CAR-T cells can Revolutionize Cancer Treatment

Cancer is the second leading cause of death in the United States, taking half a million lives each year. CAR T technology has successfully harnessed the human immune system to produce awe-inspiring cancer remission rates. CRISPR-mediated genome engineering has enabled new developments in CAR T cells to bypass logistical, technical, and immunological roadblocks, making the

No Comments InCANCER IMMUNOTHERAPY

PIER MARIA FORNASARI
2021-10-09

Difference between a COVID-19 booster shot and third dose

COVID-19 vaccine choices are getting more complicated. So don’t feel bad if you are confused about the different COVID-19 vaccines and who’s eligible for what. In addition to the three original vaccines approved by the Food and Drug Administration—Pfizer, Moderna, and Johnson & Johnson—booster shots and third doses are now available. But they are not

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-09

Anti-Platelet Factor 4 Antibodies Causing VITT do not Cross-React with SARS-CoV-2 Spike Protein

In Blood, Greinacher and colleagues examine humoral responses in vaccine-induced thrombotic thrombocytopenia (VITT) and COVID-19 to determine whether these illnesses are immunologically distinct or represent a disease continuum. At a surface level, vaccine-induced thrombotic thrombocytopenia (VITT), a recently described complication of adenoviral-based COVID-19 vaccines, and COVID-19 have much in common. Both illnesses owe their origins to severe

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-09

Convalescent plasma is “futile” as COVID-19 treatment for critically ill patients, trial published on JAMA shows

In the earliest days of the COVID-19 pandemic, the medical community turned to a century-old treatment: Take blood from recovered patients and give it to the sick. The hypothesis was that components in the so-called “convalescent plasma” that fought off the disease once could do it again, something that has worked in other diseases, such

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-09

New Study on Jama Pediatrics: Children face similar risk of SARS-CoV2 infection as adults

The new study, published in the journal JAMA Pediatrics, found adults and children living in Utah and New York City shared similar risks of becoming infected with coronavirus. But kids only had symptoms about half the time. Children are almost as likely as adults to become infected with coronavirus, but they are less likely to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-07

New study published in Pediatrics: more than 140,000 U.S. Children Lost Primary or Secondary Caregiver Due to Covid Pandemic

One U.S. child loses a parent or caregiver for every four COVID-19 deaths, a new modeling study published today in Pediatrics reveals. The findings illustrate orphanhood as a hidden and ongoing secondary tragedy caused by the COVID-19 pandemic and emphasizes that identifying and caring for these children throughout their development is a necessary and urgent part of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-06

Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments: FDA Update

While we remain vigilant to protect our families and communities from COVID-19, some people might be tempted to buy or use questionable products that claim to help diagnose, treat, cure, and even prevent coronavirus disease. Vaccination is one of the best ways to protect everyone 12 and older from COVID-19. The U.S. Food and Drug

No Comments InCovid-19

PIER MARIA FORNASARI
2021-10-06

Internet hawkers of stem cell therapies for ocular diseases

Patients have been blinded or have experienced retinal detachments after treatment with so-called stem cell therapies such as intravitreal injections of autologous stem cells that are not FDA approved for many ocular conditions across the US and that were marketed directly to patients. Currently, the FDA has regulatory authority over such companies and since June

No Comments InUNPROVEN THERAPIES

PIER MARIA FORNASARI
2021-10-06

Unapproved Stem Cell Therapies Harms Highlight Need for Greater Regulatory Enforcement

Unproven regenerative medical products have led to infections, disabilities and deaths Overview Stem cell products and other regenerative therapies have significant potential to treat traumatic injuries and serious diseases. Although some have earned approval from the Food and Drug Administration, most have not, and many of these unapproved interventions have led to life-threatening infections, chronic

No Comments InUNPROVEN THERAPIES

PIER MARIA FORNASARI
2021-10-05

COVID-19 Booster Shots

More than 180 million Americans, including more than 80 percent of people over age 65, are fully vaccinated against the SARS-CoV-2 virus responsible for COVID-19. There’s no question that full vaccination is the best way to protect yourself against this devastating virus and reduce your chances of developing severe or long-lasting illness if you do

No Comments InCovid-19

PIER MARIA FORNASARI
2021-09-03

Covid-19: 80% of young and >90% of adults in UK have antibodies: Office for National Statistics data suggest.

Around eight in ten young adults in the UK are now likely to have SARS-CoV-2 antibodies either from past infection or because they have been vaccinated, the latest survey from the Office for National Statistics has shown. The fortnightly bulletin on antibody and vaccination levels in the UK community population includes data to 13 August

No Comments InCovid-19

PIER MARIA FORNASARI
2021-08-30

Study confirms overall safety of COVID vaccine

Over the past year, results from a series of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines in preventing serious illness, hospitalizations, and deaths. Yet, with sporadic reports of rare adverse events, one question has remained unanswered: Just how safe are COVID-19 vaccines in the real world, outside of clinical trials? Now,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-08-30

Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic

A Kaiser Permanente study of nearly 200,000 children showed that children gained excess weight during the COVID-19 pandemic, especially those between 5 and 11 years old. The study was published in the Journal of the American Medical Association. “When we compared the weight gain among children from 2019 to 2020, we found that there was more

No Comments InCovid-19

PIER MARIA FORNASARI
2021-08-15

Two Alarms for Poor Prognosis After Rare VITT With AstraZeneca Jab

British doctors have identified two factors — very low platelet counts and brain bleeds — which they say dramatically increase the likelihood of a patient dying following the very rare but devastating side effect of vaccine-induced immune thrombocytopenia and thrombosis (VITT) after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. However, they believe that the surge in the VITT side

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-31

Early COVID-19 symptoms differ among age groups, research finds

Symptoms for early COVID-19 infection differ among age groups and between men and women, new research has found. These differences are most notable between younger age groups (16-59 years) compared to older age groups (60->80 years), and men have different symptoms compared to women in the early stages of COVID-19 infection. The paper, published today in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-30

CDC has updated Face Mask Recommendations for Fully Vaccinated

The Centers for Disease Control and Prevention recommends that fully vaccinated people once again wear a face mask in public in areas with substantial or high transmission of COVID-19. The Centers for Disease Control and Prevention (CDC) recommends that fully vaccinated people once again wear a face mask inside in public in areas with substantial

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-30

1.5 million kids may have lost parent, caregiver to COVID-19

More than 1.5 million children around the world have lost a parent, grandparent, or other caregiver to COVID-19, according to the first global study of its kind. In the study, published yesterday in The Lancet, a team led by US Centers for Disease Control and Prevention (CDC) scientists used death and fertility data to model minimum estimated

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-30

NICE issues new COVID-19 rapid guideline on vaccine-induced immune thrombocytopenia and thrombosis (VITT)

Patients who are acutely unwell with suspected vaccine induced immune thrombocytopenia and thrombosis (VITT) should be referred immediately to the emergency department, says new rapid guidance from the National Institute for Health and Care Excellence (NICE). National Institute for Health and Care Excellence. Covid-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) NICE guideline [NG200].

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-26

SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients

The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), becomes a global threat to humanity. In severe COVID-19 patients, excessive proinflammatory responses and impaired host immune system are observed which could result in the progression of acute respiratory distress syndrome (ARDS) and even death. In-depth investigation of SARS-CoV-2 infected

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-16

A new study analyses the rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in adults, but the incidence of COVID-19-related thrombosis in children and adolescents is unclear. Most children with acute COVID-19 have mild disease, but coagulopathy has been associated with multisystem inflammatory syndrome in children (MIS-C), a postinfectious complication.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-16

Study shows Pfizer’s COVID-19 vaccine is 78% effective during pregnancy

The full two-dose regimen of Pfizer’s COVID-19 vaccine was 78 percent effective in preventing infection among pregnant women, according to a real-world Israeli study published July 12 in JAMA. Researchers analyzed data on 7,530 pregnant women who received their first dose of Pfizer’s vaccine between Dec. 19 and Feb. 28 in Israel. The women were matched

No Comments InCovid-19

PIER MARIA FORNASARI
2021-07-16

ICER experts tussle over Aduhelm unanimously slap down new Alzheimer’s drug

Is there enough evidence to show Biogen’s new Alzheimer’s drug Aduhelm provides a benefit to patients, physicians and society beyond the current standard care? The answer from a group of ICER experts, perhaps unsurprisingly, was “no.” During a daylong meeting Thursday that featured debate over the drug’s cost and more, experts voted 15 to 0 that

No Comments InBRAIN

PIER MARIA FORNASARI
2021-07-16

EMA PRAC Concludes There is No Link Between Zynteglo and AML

EMA’s safety committee, PRAC, has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known as acute myeloid leukemia (AML). The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2021-06-30

COVID-19: the role of travel

On the eve of the summer vacation, a study assesses how newly introduced viral lineages have contributed to the resurgence of COVID-19 in Europe. It shows that in the majority of European countries, more than half of the lines circulating at the end of summer 2020 were the result of new introductions since June 15. Despite the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-30

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose. Additionally, a third dose of the vaccine continues to boost antibodies against SARS-CoV-2. The results were released in a preprint today. Delayed second dose The researchers

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-30

The European Commission has identified the first five drug candidates as part of a new strategy to select the preferred treatments for COVID-19 in the EU.

Among the five therapeutic candidates identified are Eli Lilly’s repurposed arthritis medicine Olumiant (baricitinib) and investigational antibody drugs for early-stage COVID-19. This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab. The European Medicines Agency (EMA) is currently assessing an application for the extension of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-25

Are COVID-19 vaccines effective against hospital admission with the Delta (B.1.617.2) variant ?

Vaccine effectiveness (VE) estimates against symptomatic disease with the Delta (B.1.617.2) variant have been recently reported. After a full course, VE reached 88% with the Pfizer/BioNTech BNT162b2 vaccine and 67% with the AstraZeneca ChAdOx1 AZD1222 vaccine. This provided important evidence that despite modest reductions in protection, vaccines remain effective against Delta. However, the very recent

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-05

Tokyo University of Science Scientists Find Drug Duo That May Cure COVID-19 Together

Preclinical experiments show that the drugs cepharanthine and nelfinavir may be effective treatments for COVID-19 While preventative care for COVID-19 has made much noise (with vaccines having rolled out in most countries), the soaring infection rates indicate the need for effective treatments. Using cultured cells to study SARS-CoV-2 infections, researchers at the Tokyo University of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-05

Genetic base editing shows promise for treatment of sickle cell disease

Sickle cell disease is the most common deadly genetic disorder. It results from a mutation that causes normally pliable red blood cells to become brittle and sickle shaped. This leads to pain, organ damage and early death. A team of scientists led by Mitchell J. Weiss, MD, PhD, and Jonathan Yen, PhD, at St. Jude, and David Liu,

No Comments InGENE EDITING

PIER MARIA FORNASARI
2021-06-05

Gene therapy appears more cost effective than current treatments for severe hemophilia B

St. Jude Children’s Research Hospital provides the first gene therapy manufacturing and distribution cost report for hemophilia B. A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development. The study appeared

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-06-05

A new report on Pediatrics details 7 cases of myocarditis after COVID-19 vaccination

A new report takes a close look at seven teen boys who developed myocarditis after COVID-19 vaccination, each of whom had similar symptoms, timing and outcomes. While health officials investigate whether vaccination caused this condition, Judith A. Guzman-Cottrill, D.O., a corresponding author of the report, said she hoped the report would raise clinicians’ awareness to suspect

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-04

Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant first discovered in India

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-01

A Novel Form of Macrophage-based Immunotherapy Developed by Georgia State University Has the Potential to Revolutionize Cancer Treatment

A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu. Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2021-06-01

Exploring CAR T-Cell Therapy to treat Breast Cancer

Peter MacCallum researchers are developing a potential new way to make CAR T-cell therapy more effective against breast cancer and other solid cancers. CAR T-cell therapy is a type of immunotherapy where a patient’s own immune cells are collected and reengineered, before being infused back into the patient to fight their cancer. But CAR T-cells

No Comments InCAR-T

PIER MARIA FORNASARI
2021-06-01

The future of cutting-edge gene and cell therapies

The approvals of the first gene and cell therapies in recent years have ushered in a new era of medicine. These cutting-edge approaches are poised to change the trajectory of how we treat cancer, fatal genetic conditions, and other devastating diseases. But these innovations also come with their own set of challenges, including issues of

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-06-01

Tracking SARS-CoV-2 variants

All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. WHO, in collaboration with partners, expert networks, national authorities,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-06-01

Deep Pharma Intelligence Releases Analytical Report “Cell Therapies In Healthcare Landscape Overview 2021”

Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is the first comprehensive and systematic overview of cell therapies landscape by the company. This report is specifically focused on Stem Cell therapies and Chimeric Antigen Receptor T-cell (CAR-T) therapies, and it is the first

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-06-01

Scientific evidence that informed UK Government’s response to COVID-19 including first lockdown is published in Royal Society Special Theme issue

Scientific evidence that was used to inform the UK government’s key policies impacting millions of people during the first wave of COVID-19 including the rule of six and the first national stay-at-home order is published today [31 May] in the journal of the Royal Society. The Special Theme issue is compiled and guest edited by

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-29

German researchers say Vaccine induced Thrombosis is caused by adenovirus vector and can be fixed

AstraZeneca continues to discuss the cause of rare blood clots with regulators and scientists after German researchers said they discovered the link to its Covid-19 vaccines. The U.K. pharma company said the theory put forward by the Goethe University laboratory in Frankfurt on Wednesday is one of many that AstraZeneca scientists are investigating. “We are continuing to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-29

Smart CAR-T Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials

Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer patients with solid tumors. Now, in two related papers published April 28, 2021, in Science Translational Medicine, researchers at UCSF have demonstrated how to engineer smart immune cells

No Comments InCAR-T

PIER MARIA FORNASARI
2021-05-21

EU CE marked Google’s Dermatology tool could find skin problems using just the smartphone camera and AI. Results published in Nature Medicine.

Google also announced plans to release a new “AI-powered dermatology assist tool” that helps users understand what’s going on with their skin. Results have been published in Nature Medicine. Google has made a number of announcements at I/O 2021 to showcase the company’s technological advancements. It also announced plans to release a new “AI-powered dermatology assist

No Comments InDIGITAL HEALTH

PIER MARIA FORNASARI
2021-05-21

Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools

What is already known about this topic? Kindergarten through grade 5 schools educate and address the students’ physical, social, and emotional needs. Preventing SARS-CoV-2 transmission in schools is imperative for safe in-person learning. What is added by this report? COVID-19 incidence was 37% lower in schools that required teachers and staff members to use masks

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-21

Gene therapy offers potential cure to children born with immunodeficiency due to adenosine deaminase deficiency.

Study shows treatment developed by international team restored immune function in more than 95% of patients in three clinical trials An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-05-21

A novel defense mechanism for SARS-CoV-2 discovered by researchers of Hokkaido University

Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients. In the 18 months since the first report of COVID-19 and the spread of the pandemic, there has been a large amount

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-19

Researchers identify protein “signature” of severe COVID-19: interactions among myeloid, epithelial and T cells drive tissue damage

Researchers at Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, MD, who studies interactions between

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-19

Covid-19: SARS-CoV-2 Indian Variant of concern B.1.617.2 can be 40-50% more transmissible than UK B.1.1.7.

There are many things we know and many things we don’t know about the B.1.617.2 variant. We know that it is spreading fast (roughly doubling each week in the UK and nearly tripling last week from 520 to 1313 cases), that it is becoming established in a number of areas across the country, and that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-19

Our Immune Systems Blanket the SARS-CoV-2 Spike Protein with Antibodies

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-14

Mucormycosis, a new Covid complication, is worsening India’s pandemia

Mucormycosis: hyphae of the fungus Mucor, from the paranasal sinus of a patient with diabetes mellitus. Public health officials report a rare black fungus infection, called mucormycosis, which is increasingly seen in vulnerable patients, including those with COVID-19 disease. India faces a global health crisis as the number of severe acute respiratory syndrome coronavirus 2

One comment InCovid-19

PIER MARIA FORNASARI
2021-05-14

The Application and Future Potential of mRNA Vaccines

Vaccines are often described as one of the greatest public health interventions in recent history, based on the profound effect that they have had in decreasing global morbidity and mortality. Immunizations currently prevent 2-3 million deaths each year, and aside from sanitation and clean drinking water, they are credited as having the largest impact on population growth

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-08

New research reveals why some patients may test positive for COVID-19 long after recovery

In the early months of the COVID-19 pandemic, healthcare workers analyzing test results began noticing something strange: patients who had already recovered from COVID-19 would sometimes inexplicably test positive on a PCR test weeks or even months later. Although people can catch COVID-19 for a second time, this did not appear to be the case

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-07

Fully vaccinated healthcare workers in Israel were up to 30 times less likely to be infected

Pfizer and BioNTech’s coronavirus reduces the risk of getting sick from COVID-19 by five- to 30-fold for fully immunized people, two new studies show. In one report, just 0.4 percent of healthcare workers in Israel who received both shots of the COVID-19 immunization later tested positive compared to 7.2 percent of unvaccinated employees. This means healthcare workers who

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-07

Moderna vaccine 96 percent effective in 12-17 year-olds, study shows

Moderna said its COVID-19 vaccine is 96 percent effective among youths aged 12 to 17, according to the results of its first clinical trials. Two-thirds of the 3,235 participants in trials in the United States received the vaccine and one-third were given a placebo. The study “showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-07

Norwegian-Danish registry study with findings on venous thrombosis after AstraZeneca vaccination

Norwegian and Danish researchers published a register study in BMJ of over 281,000 people who have received the AstraZeneca vaccine. – The study confirms previous findings from OUS and internationally. The registry study finds 11 additional cases of venous thrombosis among 100,000 vaccinated. The article that follows people who have received the AstraZeneca vaccine in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-06

New Cell Atlas of COVID Lungs Reveals Why SARS-CoV-2 Is Deadly and Different

A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases. Led by researchers at Columbia University Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center, the study found

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-06

COVID vaccines can take on new coronavirus variants, studies show

In a major shot in the arm for the Pfizer-BioNTech COVID-19 vaccine, researchers have reported in two studies that it is highly effective in protecting against severe COVID-19 infections caused by the variants first reported in the UK and South Africa. In a study published in the New England Journal of Medicine on May 5, researchers analysed

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-06

SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination and following lymphopenia

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is highly contagious and causes lymphocytopenia, but the underlying mechanisms are poorly understood. In this paper published on Nature fresearchers of Laboratory of Cell Engineering, Institute of Biotechnology, Beijing, China demonstrate that heterotypic cell-in-cell structures with lymphocytes inside multinucleate syncytia are prevalent in the lung tissues

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-06

Three peptides could be causing severe COVID-19 complications: proteolytic storm induces bradykinin disregulation

A study published in July 2020 hypothesized a link between the presence of bradykinin, a well-known peptide, and severe cases of COVID-19. Vardan Karamyan, Ph.D., an associate professor and vice chair for the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy Department of Pharmaceutical Sciences, had not previously conducted or

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-06

A comprehensive guide to understand how SARS-CoV-2 enters the body and drugs that could mitigate infection

In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. This protein, which cells carry on their surface, is called angiotensin converting enzyme 2 (ACE2) and provides the entry point for the coronavirus to enter cells. ACE2 is present in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-05

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year

COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, an intensified dose of thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19 and several guidelines

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-05

A Real-World Look at COVID-19 Vaccines Versus New Variants: NIH Director evaluation

Clinical trials have shown the COVID-19 vaccines now being administered around the country are highly effective in protecting fully vaccinated individuals from the coronavirus SARS-CoV-2. But will they continue to offer sufficient protection as the frequency of more transmissible and, in some cases, deadly emerging variants rise? More study and time is needed to fully

No Comments InCovid-19

PIER MARIA FORNASARI
2021-05-05

Using 4D Printing To Enable Vascularization, Bone Tissue Regeneration, Spinal Fusion

Spinal fusion is frequently performed to restore spinal stability in patients with spinal diseases, such as spinal stenosis, vertebral fractures, progressive deformities, and instability. In the past two decades, there has been marked increase in the number of people over 65 years in age who have needed spinal fusion surgery. While autogenous bone grafts have

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2021-04-30

In JAMA US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S J&J Vaccination, March 2 to April 21, 2021

Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-30

Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos published in Stem Cell Reviews and Reports

In recent years, the interest in adipose tissue mesenchymal cell–derived extracellular vesicles (AT-MSC-EVs) has increasingly grown. Numerous articles support the potential of human AT-MSC-EVs as a new therapeutic option for treatment of diverse diseases in the musculoskeletal and cardiovascular systems, kidney, skin, and immune system, among others. This approach makes use of the molecules transported

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-04-30

Francis Crick Institute @The Crick researchers uncover a naturally occurring molecule that can help coronavirus escape antibodies

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. In their research, published in Science Advances today (22 April 2021), teams from the Francis

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-23

NIH has updated COVID-19 Treatment Guidelines

The National Institutes of Health has made significant updates to its guidelines on treating people with COVID-19. What’s New in the Guidelines Last Updated: April 21, 2021 The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines is published in an electronic format that can be updated in step with the rapid pace and growing volume of information regarding the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-22

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study published on The Lancet Haematology

Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of the study, published in The Lancet Haematology was to describe management of critically ill CAR T-cell recipients in intensive care. An international, multicentre, observational

No Comments InCAR-T

PIER MARIA FORNASARI
2021-04-21

Study finds people with red hair may have higher general pain tolerance.

Research has shown that people with red hair perceive pain differently than others. They may be more sensitive to certain types of pain and can require higher doses of some pain-killing medications. However, studies suggest that their general pain tolerance may be higher. People with red hair also respond more effectively to opioid pain medications,

No Comments InRESEARCH

PIER MARIA FORNASARI
2021-04-21

One study identifies epigenetic factors that predict the severity of COVID-19

COVID-19, caused by SARS-CoV-2 virus infection, has changed human behavior patterns since it became a global pandemic. To date, more than 136 million people have suffered from the disease and, of these, more than 2.9 million have lost their lives. The symptoms of the infection vary widely, from individuals who show no clinical symptoms to those who

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-21

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) with early steroids and IVIG.

Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon. In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV‐19 vaccine induced

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-21

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant identified in California

In a paper recently published on Cell, an emerging SARS-CoV-2 variant was identified by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the Western United States. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-20

COVID-19 Vaccine J&J: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets but confirms overall benefit-risk remains positive.

At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine. In reaching its conclusion, the Committee took into

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-20

The Lernaean Hydra of post Covid-19 Vaccine Blood Clotting

For weeks, Americans looked on as other countries grappled with case reports of rare, sometimes fatal blood abnormalities among those who had received the AstraZeneca vaccine against COVID-19. That vaccine has not yet been authorized by the FDA, so restrictions on its use throughout Europe did not get that much attention in the United States.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-17

3D-Bioprinting in precision medicine: regenerative cell therapy and drug testing

Precision medicine is, broadly speaking, a sweeping aspiration that will be achieved, or not, depending on the convergence of many different disciplines. The most important of these disciplines are molecular genetics and cell biology. Besides contributing to precision medicine directly, they also contribute through 3D bioprinting. In 3D bioprinting, molecular genetics and cell biology are

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2021-04-16

In a new paper on NEJM Pathologic Antibodies to Platelet Factor 4 were found after AstraZeneca Covid Vaccine

The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. In this paper are reported findings in 23 patients who presented with

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-16

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Non pharmaceutical interventions have a higher effect on the epidemic evolution than vaccination alone.

Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model, which predicts the spread of SARS-CoV-2 infections, with a newdata-based model that projects new

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-16

For a report published by University of Oxford risk of rare blood clotting is 10 times higher for COVID-19 than for vaccines. CVST incidence is 4 for Pfizer and 5 cases per milion doses for AstraZeneca.

Researchers at the University of Oxford have today reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza. The study authors, led by Professor Paul Harrison and Dr Maxime Taquet

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-15

Risdiplam improves motor function and survival in infants with SMA

PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial of Evrysdi (risdiplam), which demonstrated that infants with type 1 spinal muscular atrophy (SMA) continued to show improvements in survival and key motor milestones after two years of treatment. PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2021-04-15

South Africa SARS-CoV-2 variant B.1.351 easily evades Sputnik vaccine

The use of this vaccine in several countries in South America and eastern Europe, besides Russia, mandates that its efficacy against the new resistant variants be tested, as they are being found more commonly in these regions.Generation of replication-competent VSV bearing SARS-CoV-2 spike (rcVSV-CoV2-S). (A) Schematic of the rcVSV-CoV2-S genomic coding construct and the virus

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

New Technique Provides Detailed Map of Lung Pathology in COVID-19. Disease progression may not depend on the persistence of the virus, but on an overreaction of the immune system.

A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases. In the study, published online March 29 in Nature, the researchers imaged autopsied lung tissue in a way that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

What is Cerebral Venous Sinus Thrombosis (CVST), the post adenovirus Covid-19 vaccine rare clotting complication: Vaccine Immune Thrombotic Thrombocytopenia represents a small percent of cases. Need to define other cases diagnosis and treatment.

Cerebral venous sinus thrombosis (CVST) occurs when a blood clot forms in the brain’s venous sinuses. This prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. This chain of events is part of a stroke that can occur in adults

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.

Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. In a paper published on The Lancet it was investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. A large, multicentre, prospective cohort study was done, with participants

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

Letter from the Expert Haematology Panel and endorsed by Thrombosis UK, to the Medicines and Healthcare products Regulatory Agency (MHRA)

We wish to raise our concern with the MHRA regarding wording included in recent changes in MHRA guidance on the use of the AstraZeneca COVID-19 vaccine. The MHRA Guidance issued 7th April 2021 (https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots ) Indicates: The MHRA is not recommending age restrictions in COVID-19 Vaccine AstraZeneca use. As a precaution, administration of COVID-19 Vaccine AstraZeneca

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-12

World Federation of Hemophilia and European Hemophilia Consortium release joint statement on AstraZeneca COVID-19 vaccine

EMA, ISTH, WHO and many countries recommend benefit of COVID-19 vaccination outweighs the risks. Risks of adverse events no higher in people with bleeding disorders The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), following investigation of isolated cases of unusual blood clotting with low blood platelets that have occurred in a small number

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

University of Cambridge: Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine

All medical treatments have potential harms as well as potential benefits, and it’s important to be able to weigh these against each other. With vaccines, the benefits are particularly complex as they can involve benefits to others as well as to ourselves – and the harms can feel particularly acute because we take vaccines when

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

In two papers on NEJM researchers find VITT as responsible of AstraZeneca’s vaccine causing clots in 16 of 222 thrombosis EMA reported cases over 30 milion doses. Even US four J&J vaccine thrombosis cases under EMA evaluation scrutiny.

Doctors might have figured out why AstraZeneca Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT) may cause life-threatening blood clots in a group of 16 patients with very rare cases of thrombosis and thrombocytopenia. The discovery, made in a pair of reports published online Friday in the New England Journal of Medicine, could be key to the global

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

New international consortium to promote stem cell-based therapy to treat Huntington’s disease

The Stem Cells for Huntington’s Disease ( SC4HD ) is a new international consortium created to drive advanced therapy drugs (ATMP), through stem cell transplantation, to treat Huntington’s disease. The entity, made up of twenty-eight renowned researchers from ten countries, has been officially featured in the Journal of Huntington’s Disease . The main objectives of the SC4HD consortium are to

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-04-09

Johnson & Johnson’s COVID-19 vaccine under EMA PRAC evaluation after 4 ‘serious cases’ of unusual blood clots

AstraZeneca’s COVID-19 vaccine has dominated headlines as reports of rare blood clots mounted, but, now, European drug safety regulators are investigating potential clotting risks from Johnson & Johnson’s vaccine. So far in the J&J vaccine’s U.S. rollout, EU officials have tracked three cases of unusual blood clots with low blood platelets following vaccination, the European

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-09

AstraZeneca COVID vaccine 70% effective vs B117 variant

Data from a UK phase 2/3 clinical trial suggest the AstraZeneca-Oxford COVID-vaccine is 70.4% effective against symptomatic COVID-19 caused by the B117 variant, which was identified in the United Kingdom in late 2020. The data, published in The Lancet yesterday, also showed it was 28.9% effective at preventing asymptomatic infections or cases with unknown symptoms. Overall efficacy was

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-09

An international working group (IWG) consensus report redefines outcomes in immune TTP

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-04-08

Antiparasitic drug could prevent Covid-19 lung damage

A common antiparasitic drug could block lung damage in people with coronavirus, new research published in Nature has found. Using robotic technology to screen over 3,000 approved drugs known to be safe in humans, researchers found Niclosamide – a drug used to treat tapeworm infections – was effective at stopping the viral replication and fusion

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-07

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

EMA confirms overall benefit-risk remains positive EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-07

Guidance produced from the Expert Haematology Panel of British Society for Haematology focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

An expert team of British Society for Haematology have recently been involved in diagnosing and managing a rare syndrome of thrombosis associated with low platelets which have been reported in a few cases. At the moment, any causal association with coronavirus vaccination has not been established. However, are identified patients with this syndrome in proximity

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-06

Ranking Virus Spillover Risk: New Web App Ranks Spillover Risk for Newly Detected Viruses

SARS-CoV-2 showed the world with devastating clarity the threat undetected viruses can pose to global public health. SpillOver, a new web application developed by scientists at the University of California, Davis, and contributed to by experts from all over the world, ranks the risk of wildlife-to-human spillover for newly discovered viruses. SpillOver is the first open-source risk

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-05

Recovered and vaccinated patients T cells recognize recent SARS-CoV-2 variants

NIH research suggests protective effects of vaccination remain intact When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-04

First FDA approval of CAR T-cell therapy for multiple myeloma marks milestone for patients

Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers

No Comments InCAR-T

PIER MARIA FORNASARI
2021-04-04

Study underscores need for multidisciplinary care for COVID-19 long-haulers

Long COVID can affect multiple organ systems and the most common symptoms include fatigue, shortness of breath, brain fog, anxiety, depression, and post-traumatic stress disorder (PTSD) Based on the limited data available, at least one-third of patients hospitalized for COVID-19 studied to date have experienced such long-term effects Physicians across the country have analyzed the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-03

Globally Accessible Therapy Is Found to Protect Against Lethal Inflammation from COVID-19 in Animal Models

Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19. In a study published today in the journal Cell, the team reported that the drug, Topotecan (TPT), inhibited the expression of inflammatory genes in the lungs

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

Potential COVID-19 treatment identified in UCLA-led lab study

Drug already in human trials as cancer therapy appears to disrupt coronavirus replication A collaboration among scientists from UCLA and other universities in California, Delaware and Germany, as well as a German pharmaceutical company, has singled out a compound that shows promise for treating SARS-CoV-2, the virus that causes COVID-19. In a series of experiments

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

A smartphone App can help to predict ‘Long COVID Syndrome’

As devastating as this pandemic has been, it’s truly inspiring to see the many innovative ways in which researchers around the world have enlisted the help of everyday citizens to beat COVID-19. An intriguing example is the COVID Symptom Study’s smartphone-based app, which already has been downloaded millions of times, mostly in the United States

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

SARS-CoV-2 infection of the oral cavity and saliva

NIH-funded findings point to a role for saliva in SARS-CoV-2 transmission. An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth. While it’s well known that the upper airways and lungs are primary sites of SARS-CoV-2 infection, there are clues the virus can infect cells

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

Individual SARS-CoV-2 neutralising antibody immunity lasts from days to decades. Patients were categorized in 5 groups: negative, rapid waining, slow waining, persistent and delayed response.

Study shows that antibody longevity varies widely from 40 days to as long as several decades and not everyone who has recovered from COVID-19 is immune from reinfection Individuals with low levels of neutralising antibodies may still be protected if they have robust T-cell immunity Blood tests and a computer algorithm suggest annual vaccinations might

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-23

Gene therapy using “zinc fingers” may help treat Alzheimer’s disease, animal study shows

Key Takeaways A single injection of a gene therapy involving what are called zinc fingers dramatically reduced levels of tau, a protein implicated in Alzheimer’s disease, in mice with the condition. The treatment was long lasting, caused no side effects, and reduced Alzheimer’s-related damage in the brain. The technology worked just the way we had

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-03-23

Retroviral gene therapy with a view on previous experience and future perspectives

Gene therapy can be used to restore cell function in monogenic disorders or to endow cells with new capabilities, such as improved killing of cancer cells, expression of suicide genes for controlled elimination of cell populations, or protection against chemotherapy or viral infection. While gene therapies were originally most often used to treat monogenic diseases

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-03-23

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools forcombating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-23

U.S. NIAID discuss results released by AstraZeneca on Covid vaccine trial: AZ might have included outdated informations.

Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-22

Aspirin use may decrease ventilation, ICU admission and death in COVID-19 patients

Researchers from the George Washington University found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-22

Astrazeneca Covid vaccine US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. No increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants.

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age,with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profile The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-21

AstraZeneca Covid vaccine and rare thrombosis: Greifswald team suggests an autoimmune trigger in 4 of 13 German reported cases. The incidence of thrombosis in Germany is 1:123.000 doses, while in the rest of Europe 1:1.350.000.

13 cases of a venous cerebral sinus or cerebral vein thrombosis following >1,6 million doses were reported in Germany. The thrombosis occurred 4-16 days after the vaccination with the AstraZeneca COVID-19 vaccine in twelve women and one man aged 20–63 years. The patients had one at the same time thrombosis and thrombocytopenia due to autoantibodies.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

New special warning introduced by EMA in the summary of COVID-19 Vaccine (ChAdOx1-S [recombinant]) product characteristics

EMA has just published the new product information leaflet for Astrazeneca Covid-19 vaccine after investigations of thrombosis rare cases reported. In the section 4.4 Special warnings and precautions for use has been added the following: Thrombocytopenia and coagulation disordersA combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, hasbeen observed very rarely following

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

A leap forward in research on CAR T cell therapy – Cellular engineering makes it possible to target the therapy also against solid tumours

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future. In cancer immunotherapy, cells in the patient’s

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-19

Optimal Thromboprophylaxis protocol in Patients With COVID-19

From the early days of the COVID-19 pandemic, a distinct coagulation disturbance of SARS-CoV-2 infection has been recognized. This thrombo-inflammatory phenotype, characterized by endotheliopathy, hypercoagulability, and coagulation activation, results in an increased risk of thromboembolic events. Initial observational cohort studies described high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19, despite consistent use

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2

In The Lancet, Zhenyu He and colleagues report their cross-sectional study of serological responses of morethan 9500 individuals from 3600 households in Wuhan, the early epicentre for the COVID-19 outbreak. The study was initiated shortly after lockdown in Wuhan ceased in April, 2020, with follow-up over two timepoints (June and October–December, 2020). In this cross-sectional,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

CDC US COVID-19 update on new SARS-CoV-2 Variants

CDC’s national genomic surveillance program identifies new and emerging SARS-CoV-2 variants to determine implications for COVID-19 diagnostics, treatments, or vaccines authorized for use in the United States. Monitoring the spread of emerging variants in the United States relies on widespread, rapid sequencing. To accelerate sequencing in the United States, CDC has contracted with commercial diagnostic laboratories, and,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

EMA Safety Committee confirms that COVID-19 Vaccine AstraZeneca benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets.

EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that: the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal)

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

A new study shows recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. A new potential role for human plasma transfusion.

Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis remain unconfirmed. In a cross-sectional cohort of 36 severe COVID-19 patients, it was shown that markedly increased plasma von Willebrand factor (VWF) levels were accompanied

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients

The main hypothesis of this retrospective study is that VWF biomarkers are associated with coagulation in COVID-19. It was performed a balanced retrospective study of COVID-19 hospitalized patients with similar demographics and comorbidities and a wide range of D-dimer levels to study how VWF biomarkers correlate with coagulation, intravascular hemolysis, and outcome. Indeed, we show

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

New Study from Cleveland Clinic Florida Researchers Points to Novel Drug Target for Treating COVID-19

Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies. Their findings were published in Nature Microbiology. Led by FRIC scientific director Michaela Gack, Ph.D., the team discovered that a coronavirus enzyme called PLpro (papain-like protease) blocks the body’s immune response to the infection. More research is necessary, but the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 (South Africa) variant.

The SARS-CoV-2 spike gene has accumulated mutations within the receptor-binding domain (RBD) and the N-terminal domain (NTD). These domains are major targets of the antibody response elicited by the vaccines. The RBD mutations include the N501Y mutation, which is associated with increased affinity of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2) receptor. In contrast, the E484K

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

Astrazeneca Covid vaccine and blood clots: a storm in a teacup

A number of European nations, including Germany, France, Italy and Sweden, have suspended use of the Oxford/AstraZeneca covid‑19 vaccine over blood clot concerns. The World Health Organization and the European Medicines Agency (EMA) have both emphasised that there is currently no evidence linking the vaccine to blood clots and recommend that countries continue using it. Emer Cooke, director of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-15

How the pandemic has impacted teen mental health. Result of a Mott Poll Report

Restrictions put in place to contain COVID-19 may be particularly difficult for teens, who rely heavily on their peer and social connections for emotional support. In 2021, the C.S. Mott Children’s Hospital National Poll on Children’s Health asked a national sample of parents about the emotional impact pandemic restrictions have had on their teens age

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-15

Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults

52,4% patients have symptoms of major depressive disorder after COVID-19, as published in a study of Massachusetts General Hospital More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder, according to a research letter published online March 12 in JAMA Network Open. Roy H. Perlis, M.D., from

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-14

Neutrophil activation tracks most closely with severe COVID-19 progression: a study on temporal and resolution dynamics of the host molecular responses confirms the main role of neutrophil proteolytic storm

The coronavirus disease-19 (COVID-19) pandemic has cost lives and economic hardships globally. Various studies have found a number of different factors, such as hyperinflammation and exhausted/suppressed T cell responses to the etiological SARS coronavirus-2 (SARS-CoV-2), being associated with severe COVID-19. However, sieving the causative from associative factors of respiratory dysfunction has remained rudimentary. In this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-13

Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants

Key Takeaways Neutralizing antibodies induced by the Pfizer and Moderna COVID-19 vaccines were significantly less effective against the variants first described in Brazil/Japan and South Africa. While the ability of these variants to resist neutralizing antibodies is concerning, it doesn’t mean the vaccines won’t be effective. Understanding which mutations are most likely to allow the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Obesity linked to higher risk for poor COVID-19 outcomes

The risk for invasive mechanical ventilation, hospitalization and death in those with COVID-19 increased with BMI, according to research published in MMWR. “The findings in this report highlight a dose-response relationship between higher BMI and severe COVID-19–associated illness and underscore the need for progressively intensive illness management as obesity severity increases,” LyudmylaKompaniyets, PhD, a postdoctoral research fellow at the CDC,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Protease inhibitors drugs Camostat and Nafamostat inhibit new SARS-CoV-2 activators identified in the upper respiratory tract, blocking virus cell entry.

There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

COVID-19 Vaccine and Blood Clots

Dr. Samuel Goldhaber, President of North American Thrombosis Forum (NATF) and Associate Chief and Clinical Director of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, answers the most pressing questions from patients about the COVID-19 vaccine and blood clots.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

UK Royal College of Physicians calls for urgent measures to protect and safeguard medical workforce involved in fight against Covid-19

In an article published in The Lancet, RCP president Professor Andrew Goddard and RCP Global vice president Dr Mumtaz Patel call for system-wide support to protect clinicians from harm. The COVID-19 pandemic has placed huge demands on global health systems which are testing doctors and health-care workers to the limits of their professional competence and taking

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Early school reopening, in absence of a robust COVID-19 mitigation, risks accelerating the pandemic

On Feb 22, 2021, the UK Government announced that schools in England would fully reopen on March 8, 2021. While returning to school as soon as possible is imperative for the education, social development, and mental and physical welfare of children, not enough has been done to make schools safer for students and staff. Primary

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

A new study on BMJ shows an increase in deaths from 2.5 to 4.1 per 1000 detected cases in SARS-CoV-2 B.1.1.7 variant

A highly infectious variant of COVID-19 that has spread around the world since it was first discovered in Britain late last year is between 30% and 100% more deadly than previous dominant variants, researchers said on Wednesday. In a study that compared death rates among people in Britain infected with the new SARS-CoV-2 variant known

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-08

The challenges of CAR T-cell therapy for pediatric B-ALL. RESTORE launched Fragments of Life: A success in the frontier of medicine becomes a video game.

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-06

Neurologic Involvement in Children and Adolescents Hospitalized in the US for COVID-19 or MISC

Most are transient, but some develop into life-threatening disorders Neurologic symptoms occurred frequently in children and adolescents hospitalized with COVID-19, a large case series of pediatric patients in the U.S. showed. Of 1,695 people 21 or younger hospitalized for acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C), more than one in five (22%) had

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-05

New Google-Backed Database Tracks Details on SARS-CoV-2 and Variants Cases Worldwide

A group of US and European epidemiologists on Tuesday launched an open international database that presents granular information on 5 million anonymized COVID-19 cases from more than 100 countries. Each case record in the database, which is housed at Global.health, contains up to 40 variables, including information such as the patient’s demographics and location, the date

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-05

Can it work a single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster in a wide vaccination strategy ?

Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa. A subsequent report of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 B.1.1.7 (UK) variant is more transmissible with a 43%-90% higher reproduction number and could induce cases resurgences.

A variant of SARS-CoV-2 that emerged in southeast England in November 2020 is more transmissible than pre-existing variants, a new modeling study of Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, published on Science, finds. Further analyses suggest the variant B.1.1.7 will lead to large resurgences of COVID-19 cases.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 variant B.1.1.7 (so called UK) is susceptible to neutralizing antibodies elicited by wild type Spike vaccines

All current vaccines for COVID-19 utilize ancestral wild type SARS-CoV-2 Spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple Spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 501Y.V1 or 20I), contains eight

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-28

NIH Fauci and BARDA Disbrow: Janssen COVID-19 Vaccine proved 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

“The Janssen COVID-19 vaccine is a very welcome addition to the arsenal of COVID-19 vaccines and other prevention strategies. When tested among 45,000 volunteers, the single-injection vaccine proved 77 percent effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85 percent effective in preventing severe/critical COVID-19 occurring at least 28 days

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-27

Carolina clinical trial tests effectiveness of mouthwash to kill oral SARS-CoV-2

Laboratory experiments have shown mouthwash can quickly kill coronaviruses, but there’s no evidence mouthwash can prevent the virus from infecting people. The Adams School of Dentistry is investigating how well mouthwash works to reduce the amount of SARS-CoV-2. Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-26

A paper published in NEJM shows that in Israel BNT162b2 mRNA Covid-19 Vaccine reduced cases by 94%

The Pfizer BioNTech coronavirus vaccine produces as good results in the “real world” as have been previously documented in randomised trials. A case control study, which has been peer reviewed and published in the New England Journal of Medicine, compared 596 618 people who were newly vaccinated in Israel and matched them to unvaccinated controls. Two doses

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Causes of death and comorbidities in hospitalized patients with COVID-19: the majority of patients had died of COVID-19 with only contributory implications of preexisting health conditions to the mechanism of death.

Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has been associated with more than two million deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of pre-existing health

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

NCI study finds that people with SARS-CoV-2 antibodies may have a low risk of future infection

People who have had evidence of a prior infection with SARS-CoV-2, the virus that causes COVID-19, appear to be well protected against being reinfected with the virus, at least for a few months, according to a newly published study from the National Cancer Institute (NCI). This finding may explain why reinfection appears to be relatively rare,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

FDA analysis:Janssen COVID vaccine is safe and effective also against Brazil and South Africa variant

The Food and Drug Administration’s staff released a briefing document on Wednesday endorsing Johnson & Johnson’s one-shot coronavirus vaccine as safe and effective. An FDA advisory panel will meet Friday to review the briefing document and vote on whether to recommend an emergency use authorization (EUA). The FDA could then issue the (EUA) as soon as this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

B.1.351 South Africa SARS-CoV-2 Variant is immune escaping but no increase in infectivity is shown in a paper on Cell

The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in Spike are now dominant in South Africa and are rapidly spreading to other countries. In this paper, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Evidence of escape of SARS-CoV-2 variant B.1.351 (South Africa) from natural and vaccine induced sera. An analysis of AstraZeneca, Pfizer, Novavax and Janssen vaccine efficacy.

The race to produce vaccines against SARS-CoV-2 began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK–B.1.1.7, South Africa–B.1.351 and Brazil–P.1. These variants have multiple changes in the immunodominant spike protein which facilitates viral cell entry via the Angiotensin

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Despite dramatic improvements in survival, multiple myeloma (MM) remains largely incurable, and most patients develop disease that is refractory to available treatment options. A paper just published on Blood Advances by researchers of Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, Division of Gastroenterology, University of Toledo, Division of Hematology and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-24

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. In this just published paper on Cell researchers of Fondazione Toscana Life Sciences, National Institute for Infectious Diseases Lazzaro Spallanzani, Imperial College London and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

European Society Blood and Marrow Transplantation Annual Report shows the rise of CAR-T Cells in Europe during year 2019 and changes in medical practices in the field of hematopoietic cell transplantation over 30 years.

Hematopoietic cell transplantation (HCT) is an established procedure for many acquired or inherited disorders of the hematopoietic system, benign or neoplastic, including those of the immune system, and as enzyme replacement in metabolic disorders. The activity survey of the EBMT, describing the status of HCT, has become an instrument with which to observe trends and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-18

Immune system protects children from severe COVID-19

Children are protected from severe COVID-19 because their innate immune system is quick to attack the virus, a new study has found. The research led by the Murdoch Children’s Research Institute (MCRI) and published in Nature Communications, found that specialised cells in a child’s immune system rapidly target the new coronavirus (SARS-CoV-2). MCRI’s Dr Melanie Neeland said the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-13

Report of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 shows 4,5 cases and 2,5 cases per million doses with Pfizer and Moderna respectively.

The cases of rash on mRNA vaccines are almost non-existent and no deaths have occurred. A research published in the medical journal JAMA, points out that the probability of developing anaphylaxis is only 0.000377%, as out of the approximately 17.5 million vaccinations, no deaths occurred, while only 66 people developed anaphylaxis to mRNA vaccines. A

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial: between them Camostat mesilate, an orally administered serine protease inhibitor.

Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Southern California COVID-19 Variant Rapidly Expands Global Reach

CAL.20C Variant, Now Found in Nearly Half of Southern California Cases, Is Detected in 19 US States, Washington, D.C., and Six Foreign Countries, Cedars-Sinai Reports A new strain of the coronavirus in Southern California, first reported last month by Cedars-Sinai, is rapidly spreading across the country and around the world as travelers apparently carry the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

NIH experts discuss SARS-CoV-2 viral variants: a Dr. Fauci’s paper on JAMA

Editorial emphasizes need for global response. The rise of several significant variants of SARS-CoV-2, the virus that causes COVID-19, has attracted the attention of health and science experts worldwide. In an editorial published today in JAMA: The Journal of the American Medical Association, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Gene Therapy development is the result of a working team.

In drug development, scientific progression was never a solo effort. Rather, to advance new therapies, particularly cell and gene therapies, drug development is a team sport. Why is the team so important? Oftentimes when one tests novel cell and gene therapies in the clinic for the first time, one is treading completely new ground. The

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-02-11

IgM have a major role in the neutralizing activity of convalescent plasma against SARSCoV-2

Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from COVID-19 patients decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-09

Artificial intelligence yields new ways to combat the coronavirus

Countering COVID-19 mutations and designing updated vaccines could occur at lightning speeds thanks to a new, USC-developed AI framework. USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial intelligence (AI),

No Comments InARTIFICIAL INTELLIGENCE Covid-19

PIER MARIA FORNASARI
2021-02-08

A new study on Nature shows that BioNTech/Pfizer vaccine should neutralize SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants.

The Pfizer / BioNTech vaccine is effective against covid-19 variants originating in the UK and South Africa. This is the result of a study published this Monday in Nature Medicine , which showed better results in the first case, the British variant (called B.1.1.7), than in the second, the South African, or B.1.351. The differences, however, are small.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

University Health Network-led study shows Peginterferon lambda speeds up clearance of COVID-19 in outpatients

A clinical study led by Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized. This could become an important intervention to treat infected patients and help curb community spread,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

Diffuse large B-cell lymphoma (DLBCL): FDA Grants Approval of 4th CAR-T Cell Therapy for Adults with Relapsed or Refractory DLBCL.

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial Breyanzi demonstrated sustained responses in patients who achieved a CR with median duration of response not reached Grade ≥3 cytokine release syndrome and Grade ≥3 neurologic toxicities following Breyanzi treatment occurred in 4% and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-08

Study highlights risk of new SARS-CoV-2 mutations emerging during chronic infection and after treatment with convalescent plasma

SARS-CoV-2 mutations similar to those in the B1.1.7 UK variant could arise in cases of chronic infection, where treatment over an extended period can provide the virus multiple opportunities to evolve, say scientists. Writing in Nature, a team led by Cambridge researchers report how they were able to observe SARS-CoV-2 mutating in the case of an

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

The mutation E484K, first identified in the South African SARS-CoV-2 variant, has now been identified in the UK fast-spreading variant

What do we know about the E484K mutation? The E484K mutation is not a new variant in itself, it’s a mutation which occurs in different variants and has already been found in the South African (B.1.351) and Brazilian (B.1.1.28) variants. The mutation is in the spike protein and appears to have an impact on the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

ORF9b from SARS-CoV-2, upon viral infection, antagonizes IFN-β and pro-inflammatory cytokines production mediating its interaction with NEMO and interrupting the K63-linked polyubiquitination of NEMO.

COVID-19 is a current global health threat caused by the novel coronavirus SARS-CoV-2. Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferons (IFNs) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. In this paper, it’s reported the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

A two-dose regimen of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant.

The Johannesburg Witwatersrand University Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, which runs the Oxford Covid-19 vaccine trial in South Africa, has announced results. In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-07

A new study confirms the CDC prediction that B.1.1.7 UK variant will dominate US Covid-19 cases by March.

A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study. Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

A not peer reviewed paper by London School of Hygiene finds a 35% increase of dying risk linked to the B.1.1.7 COVID-19 UK variant.

Since B.1.1.7 was first identified in September in southern England, it has become the dominant variant in the United Kingdom and has spread to more than 30 countries. To investigate whether the lineage causes an increased risk of dying, Nicholas Davies, an epidemiologist at the LSHTM, and colleagues analysed data from more than 850,000 people

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

Monoclonal Antibodies for Covid-19: an update

There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized patients but few for patients who are not sick enough to be hospitalized. Monoclonal antibodies are a new treatment for outpatients with COVID-19 who are at risk of progression to severe disease. What Is a Monoclonal Antibody? An antibody is a protein that is naturally

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

FDA narrows convalescent plasma Emergency Use Authorization

The US Food and Drug Administration (FDA) revised its emergency use authorization (EUA) for COVID-19 convalescent plasma to limit its use to high titer units and only in hospitalized patients who are in the early stages of the disease or who have impaired humoral immunity. Convalescent plasma emerged as a potential treatment for COVID-19 in the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

Computers can determine which could be COVID-19 patients clinical evolution

Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors. The research can be used to predict the

No Comments InCovid-19 DIGITAL HEALTH

PIER MARIA FORNASARI
2021-02-06

Investigating the modulation of the COVID-19 immune response

In a recent paper, the research team around Prof. Antonio del Sol from the University’s Luxembourg Centre for Systems Biomedicine (LCSB) describes a new method of how molecules can be identified that amplify and maintain the inflammatory response upon an infection. They use their novel method to identify these molecules in COVID-19 patients and suggest new

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

SARS-CoV-2 vaccines: how to communicate the current situation

How do vaccines work? Germs are all around us, both in our environment and in our bodies. When a person is susceptible and they encounter a harmful organism, it can lead to disease and death. The body has many ways of defending itself against pathogens (disease-causing organisms). Skin, mucus, and cilia (microscopic hairs that move debris away

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-05

SARS-CoV-2 directly infects human erythroid progenitors: implications for emerging erythropoiesis in severe COVID19 patients.

The COVID-19 pandemic continues to constitute a huge threat to public health worldwide and despite the efforts and advances to untangle the mechanisms of SARS-CoV-2 infection and transmission among humans, we are still blind to the overall COVID-19 pathology and its consequences. The results presented in this paper might help understand the emergent erythropoiesis and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Lack of ICU beds tied to thousands of excess COVID-19 deaths in US.

A new study by Yale researchers found a significant association between the availability of hospital resources — particularly ICU beds — and patient mortality during the early weeks of the COVID-19 pandemic. This was especially true at hospitals in the northeastern U.S. which were hardest hit by the first surge of patient cases, according to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Understanding COVID-19: how mRNA vaccines work. A Yale University video.

What is RNA? How do mRNA vaccines work, and how effective are they? What does this mean for the COVID-19 pandemic? In a short video, Yale experts Saad Omer, Onyema Ogbuagu, and Akiko Iwasaki explain the science.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Moffitt Researchers Identify Why CAR T Therapy May Fail in Some Lymphoma Patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-03

Heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac “Sputnik V” Found 91,6% Effective Against COVID-19: a study published on The Lancet shows

A Russian vaccine against COVID-19 — Gam-COVID-Vac (dubbed “Sputnik V”) — shows 92% efficacy in interim results from a phase 3 trial reported in The Lancet. The two-dose vaccine uses replication-deficient adenoviruses to deliver a SARS-CoV-2 glycoprotein as the antigenic stimulus. Doses are administered at 21-day intervals, and the vaccine may be stored in normal freezers.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

The timing of the booster dose is determinant for improval of immunogenicity and efficacy of ChAdOx1 (Oxford Astra Zeneca ) nCoV-19 (AZD1222) vaccine

The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, MHRA, with a regimen of two standard doses given with an interval of between 4 and 12 weeks. The planned rollout in the UK will involve vaccinating people in high risk categories with their first dose immediately, and delivering

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-02

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

In one of the most puzzling and worrisome developments in the pandemic, scientists are racing to explain what’s happening in Manaus, Brazil, a city of 2.2 million at the edge of the country’s rainforest that is experiencing a second explosive outbreak, even though the first one was so bad it was thought to have produced

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

Covid-19: B.1.1.7 new UK variant patients present more commonly sore throat, fatigue, and myalgia for Office for National Statistics

People infected with the new variant of covid-19 discovered in the South East of England (known as B.1.1.7 or VUI 202012/01) are more likely to have a cough, sore throat, fatigue, or myalgia than those infected with other variants, the Office for National Statistics has reported. The data, published 27 January, also show that people

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

Arizona University Researchers Develop Smartphone-Based COVID-19 test that uses a smartphone microscope and could deliver results in about 10 minutes.

Researchers at the University of Arizona are developing a COVID-19 testing method that uses a smartphone microscope to analyze saliva samples and deliver results in about 10 minutes. The UArizona research team, led by biomedical engineering professor Jeong-Yeol Yoon, aims to combine the speed of existing nasal swab antigen tests with the high accuracy of nasal swab PCR,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

33% can be the proportion of SARS-CoV-2 Infections That Are Asymptomatic for a Systematic Review

In the 14 studies with longitudinal data that reported information on the evolution of symptomatic status, nearly three quarters of persons who tested positive but had no symptoms at the time of testing remainedasymptomatic. Current data suggest that infected persons without symptoms—including both presymptomatic and asymptomatic persons—account for more than 40% of all SARS-CoV-2 transmission.

No Comments InCovid-19 Uncategorized

PIER MARIA FORNASARI
2021-02-01

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial shows reduction risk of heart failure hospitalizations.

1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%. 2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared to placebo. Evidence Rating Level: 1

No Comments InRESEARCH

PIER MARIA FORNASARI
2021-01-31

For CDC, in-Person Schools May Reopen with Precautions as Data Shows Scant Virus Spread

U.S. schools operating in-person have experienced low transmission of the Chinese coronavirus, particularly when mitigation strategies such as masking and social distancing are in place, U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky stressed on Friday, citing new findings by the health agency. Under President Joe Biden, the CDC has expressed support

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-31

SARS-CoV-2 VS vaccines and the threat of mutations

The key question in 2021 is whether the new strains of coronavirus will be able to eradicate the vaccine-induced immunity. This paper on JAMA by John P Moore and Paul A Offit of Cornell and Pennsylvania Universities has been recently published on JAMA. The protection that vaccines provide against COVID-19 infection is mediated primarily by

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-29

Who does and who doesn’t benefit from steroids for Covid-19. Results from a meta-analyses of RCTs.

Efficacy and safety of corticosteroids in patients with SARS-CoV-2 infection still are debated. Because large randomized clinical trials (RCTs) and a well-conducted meta-analysis on the use of corticosteroids, focused on patients with coronavirus disease (COVID-19) in intensive care units, recently were published, a meta-analysis of RCTs on corticosteroids therapy in patients with different disease severity

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-29

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

An international team of researchers has characterized the effect and molecular mechanisms of an amino acid change in the SARS-CoV-2 Spike protein N439K. Viruses with this mutation are both common and rapidly spreading around the globe. The peer reviewed version of the study appears January 25 in the journal Cell. Investigators found that viruses carrying this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-25

The Future of Organ Transplants: Bioprinting, Stem Cells and More. A paper of Polylactide.com

In the United States alone, over 100,000 people are on the organ transplant list. Around 17 of these people will die per day without having received the transplant. It’s clear that organs from human donors will never be adequate for everyone looking for a transplant. Thus, scientists have been researching alternatives, such as using organs made from repurposed stem

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2021-01-25

The effects of armed conflict on the health of women and children. More than 10 million deaths in children <5 years can be attributed to conflict between 1995 and 2015 globally.

Women and children bear substantial morbidity and mortality as a result of armed conflicts. This paper published in The Lancet focuses on the direct (due to violence) and indirect health effects of armed conflict on women and children (including adolescents) worldwide. It was estimate that nearly 36 million children and 16 million women were displaced

No Comments InETHICS INFORMATION

PIER MARIA FORNASARI
2021-01-25

A Clalit study shows decreased infection in SARS-CoV-2 due to the Pfizer vaccine

The Clalit Research Institute is currently examining the effect of the vaccine against the coronavirus developed by Pfizer. Preliminary data show that 14 days after the injection of the first vaccine, there is a real decrease in the rate of infection in the corona . The study compared the infection data of about 200,000 people aged 60 and over who

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-25

CDC reports 2,5 Anaphylaxis Cases per million Moderna Covid-19 vaccine doses in USA.

As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-23

Creating a Safe CAR T-Cell Therapy to Fight Solid Tumors in Children

Scientists at Children’s Hospital Los Angeles develop newer CAR T therapy that promises to be more effective and less toxic for children with neuroblastoma. Chimeric Antigen Receptor T-cell therapy—CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using certain CAR

No Comments InCAR-T

PIER MARIA FORNASARI
2021-01-22

11,1 cases per million doses Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Following implementation of vaccination, reports of anaphylaxis after the first dose of the Pfizer-BioNTech COVID-19 vaccine emerged.Anaphylaxis is a life-threatening allergic reaction that occurs rarelyafter vaccination, with onset typically within minutes to hours.Notifications and reports of suspected severe allergic reactions and anaphylaxis following vaccination were captured in the Vaccine Adverse Event Reporting System (VAERS), the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

Emergence of a novel SARS-CoV-2 strain in Southern California, USA

Researchers in Cedars-Sinai Medical Center, Los Angeles found that the variant, originated in California, was present in more than half of samples tested last week by researchers in Los Angeles. In late December, scientists in California began searching coronavirus samples for a fast-spreading new variant that had just been identified in Britain. They found it, though in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

Review of the epidemiology, susceptibility to infection, pathophysiology, immunology, complications, potential therapeutic options and response to vaccinations in people with diabetes, obesity and metabolic disorders showing mortality excess due to SARS-CoV-2 infection.

The increased prevalence of obesity, diabetes and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. In this paper published in Cell Metabolism are updated concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

A study shows early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. In this paper published on Cell Reports are interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. SARS-CoV-2 viral RNA in the respiratory tract in parallel

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

Autoantibodies role suspected in severe Covid-19 patients

Evidence is growing that self-attacking ‘autoantibodies’ could be the key to understanding some of the worst cases of SARS-CoV-2 infection. More than a year after COVID-19 emerged, many mysteries persist about the disease: why do some people get so much sicker than others? Why does lung damage sometimes continue to worsen well after the body

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

New study shows that BioNTech-Pfizer SARS-CoV-2 vaccine protects against highly infectious UK variant

A new study found that antibodies in patients vaccinated against COVID-19 were able to neutralize a version of the new variant. Researchers tested 10 mutations of the B117 variant, which was first identified in the UK. The COVID-19 vaccine developed by BioNTech and Pfizer is likely to protect against the highly infectious variant of the virus, originally found

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19, due to its inhibition of neutrophil serine proteases “unfriendly fire”.

No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-20

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. In a paper recently published on https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1.full.pdf it’s shown that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantial or complete escape from neutralizing antibodies in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-20

B.1.1.7 SARS-CoV-2 (UK) and other variants description

At the heart of each coronavirus is its genome, a twisted strand of nearly 30,000 “letters” of RNA. These genetic instructions force infected human cells to assemble up to 29 kinds of proteins that help the coronavirus multiply and spread. As viruses replicate, small copying errors known as mutations naturally arise in their genomes. A lineage of coronaviruses will

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Update on new SARS-CoV-2 emerging variants (UK, South Africa, Brazil and California)

What do we know about the new variant emerging from Brazil? This variant, known as P.1 or VOC202101/02 in the UK, was first detected in travellers from Brazil who arrived in Japan in January 2021. It involves 17 unique amino acid changes, three deletions, four synonymous mutations, and one 4nt insertion. It has several mutations

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug

Research conducted by the University of Bari in collaboration with the Campus Bio-Medico University of Rome The studies carried out by the research team of the University of Bari in collaboration with the Campus Bio-Medico University of Rome, formed by Luigi Leonardo Palese, Anna Maria Sardanelli, and Camilla Isgrò of the Department of Basic Medical

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-18

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes

A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both therapies work by switching on a gene that promotes production of fetal hemoglobin, said Dr. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-01-17

Saliva tests may be just as good as nasopharingeal swabs for COVID-19

COVID-19 tests that use patients’ saliva to screen for the virus are just as effective as those that use swabs collected from the nose and throat, an analysis published by JAMA Internal Medicine found. Saliva-based tests correctly identified those infected with the new coronavirus 83% of the time, while nose-throat swab tests were 85% accurate, the review of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

For CDC the more contagious SARS-CoV-2 B.1.1.7 variant may soon be the U.S.’s dominant strain

On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of concern (VOC), lineage B.1.1.7, also referred to as VOC 202012/01 or 20I/501Y.V1.* The B.1.1.7 variant is estimated to have emerged in September 2020 and has quickly become the dominant circulating SARS-CoV-2 variant in England (1). B.1.1.7 has been detected in over 30 countries,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19, due to no convincing evidence of the effect on clinical outcomes.

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19. Since May 2020, the RECOVERY trial has included a randomised comparison of convalescent plasma vs. usual care alone. Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-15

The Future of CAR T cells in multiple myeloma

Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall

No Comments InCAR-T

PIER MARIA FORNASARI
2021-01-12

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19: observational study published in Gut BMJ.

Imbalances in type and volume of bacteria may also be implicated in ‘long COVID’ The variety and volume of bacteria in the gut, known as the microbiome, may influence the severity of COVID-19 as well as the magnitude of the immune system response to the infection, suggests research published online in the journal Gut. Imbalances in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-12

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca. Marketing authorisation could be issued by 29 January

EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

A CDC study published on JAMA shows that People without symptoms spread SARS-CoV-2 in more than half of cases.

A model developed by CDC researchers estimates that 59% of coronavirus cases in the United States are spread by asymptomatic carriers. Transmissions from individuals who have not yet begun to exhibit signs of infection account for 35% of that total, while transmissions from people who never develop symptoms make up the other 24%. A model

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Regulatory perspectives of Exosomes as therapeutics and drug delivery vehicles

Exosomes are nano-sized extracellular vesicles secreted by all cells. Extensive research over recent years has now shown these vesicles to be important players in intercellular signalling and to have a role in tissue regeneration, immunomodulation and other biological functions. A lipid bilayer protects the exosome cargo of nucleic acids and proteins from degradation and permits

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2021-01-11

Placental Protection : Three studies examine coronavirus and antibodies during pregnancy

Pregnant women infected with SARS-CoV-2 appear to be at higher risk of developing severe cases of COVID-19 than infected women who are not pregnant. Yet newborns are mostly doing well. Reports indicate that only about 5 percent of babies born to COVID-19-infected mothers are themselves infected, and most newborns who test positive have mild or

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Candida Auris Outbreak in a COVID-19 Specialty Care Unit in Florida

Dozens of people being treated for COVID-19 at a Florida hospital last summer became additionally infected with a mysterious, often deadly fungus called Candida auris, a US government study said Friday. The multidrug-resistant yeast was first identified in Japan in 2009 and has been a top priority for the Centers for Disease Control and Prevention

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Study finds higher burden of acute brain dysfunction for COVID-19 ICU patients

COVID-19 patients admitted to intensive care in the early months of the pandemic were subject to a significantly higher burden of delirium and coma than is typically found in patients with acute respiratory failure. Choice of sedative medications and curbs on family visitation played a role in increasing acute brain dysfunction for these patients. That’s

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

For U.K. health officials, Interleukin-6 inhibitors (Tocilizumab or Sarilumab) should be prescribed to adult patients admitted to ICU with Covid-19 pneumonia.

Clinicians should consider prescribing intravenous tocilizumab following the criteria defined below for patients in intensive care. Intravenous sarilumab could be considered as an alternative (if available).Any provider organisation treating patients with this intervention will be required to assure itself that the internal governance arrangements have been completed before either medicine is prescribed. These arrangements may

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

An In Vitro Study Shows Pfizer-Biontech COVID-19 Vaccine Elicits Neutralizing Antibodies against SARS-COV-2 with N501Y Mutation

Pfizer Inc. and BioNTech SE announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-10

What we know about genetic variants of SARS-CoV-2

When we speak of variants we refer to differences in the sequence of the genome due to mutations. Strain is a variant in which changes in its biology are demonstrated (antigenicity, transmissibility, virulence,…). For now, let’s talk about variants. The evaluation of the new variants should answer these questions: Has the new variant appeared by

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-08

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff

Impact on molecular tests remains low The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-08

Orchard Therapeutics with research alliance partners Fondazione Telethon and Ospedale San Raffaele Milan Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

First gene therapy to receive full EU marketing authorization for eligible MLD patients. One-time treatment with Libmeldy has been shown to preserve motor and cognitive function. Orchard Therapeutics, a global gene therapy leader, and its research alliance partners Fondazione Telethon and Ospedale San Raffaele, today announced that the European Commission (EC) granted full (standard) market authorization

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-01-08

DNA-editing method shows promise to treat mouse model of progeria

Using a recently developed DNA base-editing technique, researchers correct accelerating aging disorder. Researchers have successfully used a DNA-editing technique to extend the lifespan of mice with the genetic variation associated with progeria, a rare genetic disease that causes extreme premature aging in children and can significantly shorten their life expectancy. The study was published in the journal Nature, and was

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-01-07

Stem cell treatment corrects skull shape and restores brain function in mouse model of childhood disorder

Scientists regenerate parts of the skull affected by craniosynostosis, a common birth defect. Using stem cells to regenerate parts of the skull, scientists corrected skull shape and reversed learning and memory deficits in young mice with craniosynostosis, a condition estimated to affect 1 in every 2,500 infants born in the United States, according to the

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-01-07

ApoE isoform-dependent SARS-CoV-2 neurotropism and cellular response

ApoE4, a strong genetic risk factor for Alzheimer’s disease, has been associated with increased risk for severe COVID-19. However, it is unclear whether ApoE4 alters COVID-19 susceptibility or severity and the role of direct viral infection in brain cells remains obscure. In this paper, published in Cell Stem Cells, the Authors tested the neurotropism of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-07

Early IgG titer greater than 1:1000 against SARS-CoV-2 spike protein Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. In this paper, published on NEJM, the Authors conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-06

The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19

Corticosteroid therapy is now recommended as a treatment in patients with severe COVID-19. But one key question is how to objectively identify severely ill patients who may benefit from such therapy. In a paper just published on Cell Metabolism, 12,862 COVID-19 cases from 21 hospitals in Hubei Province were equally assigned to a training and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-05

Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage

The proximal origins of SARS-CoV and MERS-CoV from civets and camels, respectively, are well documented. Few genetic changes in these viruses are required for the interspecies transfers to humans. While precise details and timing of the evolutionary pathways remain to be elucidated, it is also apparent that SARS-CoV-2 emerged from the Sarbecovirus subgenus of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-05

SARS-CoV-2 Variants

SARS-CoV-2, the virus that causes COVID-19, has had a major impact on human health globally; infecting a large number of people; causing severe disease and associated long-term health sequelae; resulting in death and excess mortality, especially among older and vulnerable populations; interrupting routine healthcare services; disruptions to travel, trade, education and many other societal functions;

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-01

New SARS-CoV-2 variants described by researchers of University College of London and Cambridge University

Does it spread more easily? Make people sicker? Mean that treatments and vaccines won’t work? Questions are multiplying as fast as new variants of the coronavirus, especially the one moving through England and now popping up in the U.S. and other countries. Scientists say there is reason for concern and more to learn but that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-01

Microvascular Injury in the Brains of Patients with Covid-19. The damage was not caused by a direct viral attack on the brain.

In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-30

Oxford University/AstraZeneca Covid-19 vaccine approved by UK MHRA

The new vaccine has been approved today after meeting the required safety, quality and effectiveness standards. The COVID-19 vaccine developed by Oxford University/AstraZeneca has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting required safety, quality and effectiveness standards. Following a rigorous, detailed scientific review by the MHRA’s

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-29

Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction

Severe coronavirus disease 2019 (COVID-19) is characterized by the intense formation of neutrophil extracellular traps (NETs), leading to the occlusion of microvessels, as shown in pulmonary samples. The occurrence of ST-elevated myocardial infarction (STEMI) is a serious cardiac manifestation of COVID-19; the intrinsic mechanism of coronary thrombosis appears to still be unknown. Objective of the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-29

One Year Later, How Does COVID-19 Affect Children?

Children get sick less often than adults due to Covid-19, but children are at risk. This is the key insight from a paper in the Journal of American Medical Association (JAMA), a peer-reviewed medical journal, as the year draws to an end. The paper summarizes the current understanding of how children are affected by Covid-19. So far

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-28

SARS-CoV-2 vaccine update

Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 64 vaccines in clinical trials on humans, and 19 have reached the final stages of testing. At least 85 preclinical vaccines are under active

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-27

D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction

The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. In this paper are explored spike conformational changes and the effects of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-27

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19

The SARS-CoV-2 pandemic poses an unprecedented public health crisis. Evidence suggests that SARS-CoV-2 infection causes dysregulation of the immune system. However, the unique signature of early immune responses remains elusive. In this paper the transcriptome of rhesus macaques and mice infected with SARS-CoV-2 was characterized. Alarmin S100A8 was robustly induced in SARS-CoV-2 infected animal models

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-20

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Recently a distinct phylogenetic cluster (named lineage B.1.1.7) was detected within the COG-UK surveillance dataset. This cluster has been growing rapidly over the past 4 weeks and since been observed in other UK locations, indicating further spread. Several aspects of this cluster are noteworthy for epidemiological and biological reasons and we report preliminary findings below.

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-18

Which appropriate SARS-CoV-2 test to select.

There’s a growing variety and availability of tests related to SARS-CoV-2. All types of tests can help healthcare providers make more accurate diagnosis, support better management of individual patients and provide better guidance to manage population risk. Active infection is detected with RT-PCR tests detect the presence of SARS-CoV-2 based on its genetic make up (RNA). These tests

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-18

By October 2020 COVID-19 had become the third leading cause of death in US for persons aged 45 through 84 years and the second for those aged 85 years or older.

Adults 45 years or older were more likely to die from COVID-19 during those months than from chronic lower respiratory disease, transport accidents (eg, motor vehicle fatalities), drug overdoses, suicide, or homicide. In contrast, for individuals younger than age 45 years, other causes of death, such as drug overdoses, suicide, transport accidents, cancer, and homicide

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-16

Teaching youngsters about the magnificent world of Advanced Therapies. RESTORE Consortium experiences a new formation/information tool for disseminating CAR-T Cells Therapy in Haematologic diseases.

“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-12-15

Research Could Offer Novel Way to Restore Lung Function to COVID-19 Patients

Targeting endothelial cells –cells that comprise the blood vessel wall which regulate oxygen exchange between airways and the bloodstream– may be a novel approach restoring normal lung function to Covid-19 patients with serious lung disease. This hypothesis stems from a study by researchers in the Department of Microbiology and Immunology in the Renaissance School of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-15

Covid-19 fighting: New Online Resources

There are lots of useful online resources to learn about COVID-19 and some of the clinical studies taking place across the country. What’s been missing is a one-stop online information portal that pulls together the most current information for people of all groups, races, ethnicities, and backgrounds who want to get involved in fighting the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-14

Data Monitoring Committee of Pluristem Phase III Critical Limb Ischemia says primary endpoint has not been reached

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-12-12

New Online COVID-19 Mortality Risk Calculator Could Help Determine Who Should Get Vaccines First

CALCULATOR GENERATES MORTALITY RISK ESTIMATES FOR INDIVIDUALS AND COMMUNITIES BASED ON SOCIODEMOGRAPHIC INFO AND MEDICAL HISTORY A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers who developed the calculator expect it to be useful to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-12

Genes could be key to new Covid-19 treatments

Potential treatments for Covid-19 have been identified after the discovery of five genes associated with the most severe form of the disease. Genetic evidence is second only to clinical trials as a way to tell which treatments will be effective in a disease. Existing drugs that target the actions of the genes reveal which drugs

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic

During the coronavirus disease 2019 (COVID-19) pandemic, the general public has been advised to wear masks or improvised face coverings to limit transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there has been considerable confusion and disagreement regarding the degree to which masks protect thewearer from airborne particles. To evaluate the fitted filtration

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

Repurposed Antiviral Drugs for Covid-19 —Interim WHO Solidarity Trial Results confirmed none of tested drugs reduced mortality

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir and interferon beta-1a) in patients hospitalized with Covid-19. Inpatients with Covid-19 were randomly assigned equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

FDA Vaccines and Related Biological Products Advisory Committee Recommends COVID-19 Vaccine For Emergency Use

In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic. The vote in favor of the vaccine was taken to answer the agency’s question: Do the benefits

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-10

Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARSCoV-2-Infected Cells

Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells (MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome (ARDS). Thus, multiple clinical trials assessing the potential of MSCs for COVID-19 treatment are underway. Yet, as SARS-inducing coronaviruses infect stem/progenitor cells, it is unclear whether MSCs could be infected by SARS-CoV-2 upon

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2020-12-10

COVID-19, cold, allergies and the flu: What are the differences?

COVID-19, the common cold, seasonal allergies and the flu have many similar signs and symptoms. Find out about some of the important differences between these illnesses. If you have signs or symptoms of coronavirus disease 2019 (COVID-19), it’s important that you contact your doctor or clinic right away for medical advice. But COVID-19, the common cold,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-10

COVID-19’s sex bias based on a large-scale global statistical analysis: men more at risk of requiring critical care

Sex should be considered an important biological factor when designing therapies and vaccination strategies for COVID-19. Global-scale collaboration between scientists has taken on new forms in the midst of the COVID-19 pandemic, with connection underpinning the work. A paper investigating the role of sex in patients infected with COVID-19 is the result of a partnership between researchers

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-09

Researchers at Gladstone Institutes Identify Critical Molecules that Coronaviruses Hijack to Infect Human Cells

When a coronavirus—including SARS-CoV-2, which causes COVID-19—infects someone, it hijacks the person’s cells, co-opting their molecular machinery for its own survival and spread. Researchers at Gladstone Institutes and the Chan Zuckerberg Biohub, in collaboration with scientists at UC San Francisco (UCSF) and Synthego Corporation, have identified critical molecular processes in human cells that coronaviruses use

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-08

3D VR video on CAR-T therapy to learn more about how this innovative technology is being used to tackle MultipleMyeloma.

The Janssen Pharmaceutical Companies of Johnson & Johnson unveils longer-term results from the combined Phase 1b/2 CARTITUDE-1 study evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma. Cilta-cel is an experimental BCMA-directed (B cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy. Data presented at the ongoing Annual Meeting

No Comments InCAR-T

PIER MARIA FORNASARI
2020-12-08

Oxford–AstraZeneca COVID-19 vaccine efficacy: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK published on The Lancet

2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials, with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-07

New CRISPR-Based Test for COVID-19 Uses a Smartphone Camera

A team of scientists from Gladstone, UC Berkeley, and UC San Francisco outlined the technology for a rapid, one-step mobile test that could help combat the pandemic and fully reopen communities. Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-05

Presented CAR T ZUMA-5 phase 2 study data for non-Hodgkin lymphoma

Earlier this year, Caron Jacobson, MD, presented the interim analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Results from that interim analysis showed that the vast majority of patients with follicular lymphoma or marginal zone lymphoma – two slow-growing forms of non-Hodgkin lymphoma – responded to and

No Comments InCAR-T

PIER MARIA FORNASARI
2020-12-04

Moderna mRNA-1273 Vaccination produced serum neutralizing antibodies detected in all the participants at day 119

Vaccine “has the potential to provide durable humoral immunity” against virus, NIAID authors argue Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated. Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-02

Toward superhuman SARS-CoV-2 immunity?

Vaccines against covid could give “superhuman immunity”, stronger than if the disease is passedThe researchers Dennis Burton and Eric Topol have published in ‘Nature’ a correspondence in which they address the perspectives of the immunity of vaccines, comparing the available data on covid vaccines with those on vaccines against other diseases. They are optimistic that

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-01

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

The coronavirus can reach the human brain after it is inhaled through a person’s nose and becomes trapped in the nasal mucus, a study found. It is the first known evidence that the coronavirus can infect neurons of the brain through the mucosal pathway. In the course of the pandemic, it has become clear that

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-01

Penn Medicine Researchers Unlock the Door to Tumor Microenvironment for CAR T Cells

PAK4 inhibitor improved T cell infiltration and shrank solid tumors in mice The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors. Now, in a new study published online today in Nature Cancer, Penn Medicine researchers found that combining chimeric antigen receptor (CAR)

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-27

PEDSnet Report Details How COVID-19 Pandemic Has Affected Children

Analysis of 135,000+ medical records shows the novel coronavirus hits hardest among teens, children with diabetes or cancer, lower-income families, and Black, Latin and Asian groups. In the most comprehensive analysis to date of U.S. children tested and treated for COVID-19, an organization representing seven of the nation’s largest pediatric medical centers reports that some

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-27

Big Data Powers Design of ‘Smart’ Cell Therapies for Cancer

Combining Machine Learning with Cell Engineering, Scientists Can Design ‘Living Medicines’ that Precisely Target Tumors Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies to crack this problem with “smart”

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2020-11-26

CAR T-Cell Research is surging accompanied by a diversification of development and manufacturing pathways.

Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-26

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia fails to shows significant clinical benefit as compared with placebo.

Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. In this paper researchers of the Clinical Pharmacology Section, Hospital Italiano de Buenos Aires, Juan D. Perón, Buenos Aires, Argentina as

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-25

Drug guides stem cells to desired location, improving their ability to heal

Discovery represents a major milestone for regenerative medicine that could help more people benefit from stem cell therapy. Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and a major advance for the field of regenerative medicine. The

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2020-11-25

Most Americans are still vulnerable to SARS-CoV-2 virus. Seroprevalence over 4 collection periods ranged from less than 1% to 23%

As of September, the vast majority of Americans did not have coronavirus antibodies, according to a new study published in JAMA Internal Medicine. These data matter as the coronavirus spreads rapidly throughout most of the country, most people remain vulnerable to it. Across the U.S., the portion of states’ populations with detectable antibodies ranged from less

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-24

Insulin treatment is associated with increased mortality in patients with COVID-19

COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-24

Antibodies capable of neutralising SARS-CoV-2 persist for at least 3 months in most Covid-19 patients, even those who had mild disease.

The SARS-CoV-2 virus is causing a global pandemic and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. In this paper, published on Cell, it’s performed a longitudinal assessment of individuals recovered from mild

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-22

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis published on EClinicalMedicine.

Early reports indicated that in COVID-19 may be associated with coagulation dysfunction. Studies have reported varying rates of thromboembolism. In this paper, the Authors searched PubMed, Cochrane and Embase for systematic reviews and meta-analyses evaluating thromboembolism rates in COVID-19 published until June 12, 2020. The search terms were “COVID-19”, “SARS-CoV-2” or “novel coronavirus” and “venous

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

Oxford coronavirus vaccine produces strong immune response in older adults as published in The Lancet

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

The Most Logical Approach to Improve CAR T Cell Therapy: a preview on Cell Systems

Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity. Immunotherapy, including biologic and cellular approaches, is a critical area of focus for cancer therapeutics. Of the methodologies used

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-20

Baricitinib treatment linked to reduced mortality in COVID-19 patients

The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials. “We are pleased to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19

As of 20 November 2020, the number of COVID-19 cases was reported to be more than 57 million, leading to more than 1.361,000 deaths worldwide . Elevated levels of CRP, cytokine and chemokines, together with low lymphocyte and eosinophil counts, characterize patients with severe disease. However, a reliable biomarker of poor outcome in COVID-19 is

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-19

In the lab, St. Jude scientists redefine cytokine storm and identify possible COVID-19 treatment

Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs. The COVID-19 pandemic continues to cause significant illness and death while treatment options remain limited.St. Jude Children’s Research Hospital scientists have discovered a potential strategy to prevent life-threatening

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-18

Pfizer and BioNTech conclude Phase 3 study of Covid-19 Vaccine candidate, meeting all primary efficacy endpoints

Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-17

Data released by the American Academy of Pediatrics and the Children’s Hospital Association find that more than 1 million kids have now been diagnosed with Covid-19.

State-level reports are the best publicly available data on child COVID-19 cases in the United States. The American Academy of Pediatrics and the Children’s Hospital Association are collaborating to collect and share all publicly available data from states on child COVID-19 cases (definition of “child” case is based on varying age ranges reported across states;

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-17

For an Oxford University research, videogaming is positively correlated with well-being. RESTORE consortium videogame “Fragments of Life” helps to enter into CAR-T Cells breakthrough therapy in Acute Lymphoblastic Leukemia.

Conventional wisdom has it that too many cooks spoil the broth. But such judiciousness is not usually considered the basis for scientific pronouncements or international rulings on the need to limit the number of people in kitchens. But, when it comes to video games, conventional wisdom, not science, forms the basis for our thinking and

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CAR-T

PIER MARIA FORNASARI
2020-11-16

CAR-T cell therapy as a “game changer” therapy in paediatric acute lymphoblastic leukaemia: past, present and future. A review of the British Society for Haematology.

Over the last decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment modality for relapsed/refractory B-cell malignancies in both children and adults. As an adoptive immune therapy, CAR-T cells have the potential to overcome disease that is resistant to chemoand radiotherapy as well as represent a viable option for those who

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-16

Clinical Trial of NIH-Moderna COVID-19 Vaccine: Positive Interim Results

An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic

2 comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

Dissecting the immune characteristics of severe COVID-19 responses: Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19

Key points: Researchers have analysed immune cell types and numbers from the blood of healthy volunteers, COVID-19 patients experiencing mild-to-moderate effects and patients classified as severe to understand whether particular characteristics of their immune system response can identify treatment targets or indicate disease severity. After comparing the T cell immune response, the researchers noted the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. SARS-CoV-2 infection of pancreatic endocrine cells, via ACE2, is an unlikely central pathogenic feature.

Diabetes is associated with increased mortality from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Given literature suggesting a potential association between SARS-CoV-2 infection and diabetes induction, it was examined pancreatic expression of angiotensin-converting enzyme-2 (ACE2), the key entry factor for SARS-CoV-2 infection. Specifically, in this paper published on Cell Metabolism, were analyzed five public scRNA-seq pancreas

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways: an investigation on the phylogenetic characteristics of SARS-CoV-2 infections in Chicago.

The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID-19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. In this paper it’s investigated the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois, and assessed their relationship to clinical parameters. Whole-genome sequencing of SARS-CoV-2 isolates

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

A Series of Disappointing Results of Immune-Based Therapies for COVID-19

It’s been a tough couple of weeks for immune-based therapies for COVID-19. We know that immune modulation in this disease, especially in its most severe manifestations, can improve outcomes. Favorable results from the RECOVERY study of dexamethasone have made it the standard of care for most hospitalized patients who require oxygen. And we also know that our own immune

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

Treatments for People with Early COVID-19 Infection is an Urgent Research Focus, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues.

Effective, Early Interventions would Benefit Individual Patients and Healthcare System COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues. Treating people early in the course of infection with SARS-CoV-2, the virus that causes COVID-19, would speed their recovery, reduce

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

Real-time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles with four distinct FRET efficiency states, enhanced by proteolysis. Convalescent plasma antibodies exert a double action.

SARS-CoV-2 spike (S) mediates viral entry into cells and is critical for vaccine development against COVID-19. Structural studies have revealed distinct conformations of S, but real-time information that connects these structures, is lacking. In this paper it’s applied single-molecule Fluorescence (Förster) Resonance Energy Transfer (smFRET) imaging to observe conformational dynamics of S on virus particles.

6 comments InCovid-19

PIER MARIA FORNASARI
2020-11-13

Inhaled nebulised Interferon beta-1a may help Covid-19 patients, in a randomised, double-blind, placebo-controlled, phase two trial.

An inhaled form of interferon — a drug commonly used to treat multiple sclerosis by injection — may help protect hospitalized Covid-19 patients from getting worse, according to a British drugmaker. Results were first released in July, but were published Thursday as a peer-reviewed study in The Lancet Respiratory Medicine. The body naturally releases interferon when

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-12

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial

An obsessive compulsive disorder (OCD) drug may help improve the conditions of coronavirus patients, a new study suggests. Fluvoxamine, sold under the brand name Luvox, is a medication that scientists believe has anti-inflammatory properties, which can help control the immune system’s overreaction to the virus. No patient who was given the drug suffered from shortness of breath

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-11

Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US FDA

To understand the usual approval process followed by the FDA, researchers of the Yale University School of Medicine have systematically evaluated all novel vaccines approved by the FDA over the last decade, characterizing the premarket development and regulatory review times, the clinical evidenceon which approval was based, and the size and follow-up duration of the